
## Andrew N Phillips

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8322562/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1459-1544.	13.7	4,934
2	Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. New England Journal of Medicine, 2015, 373, 795-807.	27.0	2,232
3	CD4+ Count–Guided Interruption of Antiretroviral Treatment. New England Journal of Medicine, 2006, 355, 2283-2296.	27.0	2,099
4	Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. New England Journal of Medicine, 2003, 349, 1993-2003.	27.0	1,560
5	Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet, The, 2016, 387, 53-60.	13.7	1,493
6	Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet, The, 2002, 360, 119-129.	13.7	1,415
7	Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. New England Journal of Medicine, 2007, 356, 1723-1735.	27.0	1,393
8	Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet, The, 1998, 352, 1725-1730.	13.7	1,182
9	Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet, The, 2003, 362, 22-29.	13.7	1,157
10	Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. JAMA - Journal of the American Medical Association, 2016, 316, 171.	7.4	1,076
11	Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus. Archives of Internal Medicine, 2006, 166, 1632.	3.8	1,004
12	Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet, The, 2008, 371, 1417-1426.	13.7	809
13	Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. Aids, 2003, 17, 1179-1193.	2.2	770
14	Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet, The, 2014, 384, 241-248.	13.7	767
15	High Coverage of ART Associated with Decline in Risk of HIV Acquisition in Rural KwaZulu-Natal, South Africa. Science, 2013, 339, 966-971.	12.6	700
16	Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet, The, 2009, 373, 1352-1363.	13.7	676
17	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet, The, 2019, 393, 2428-2438.	13.7	627
18	HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ: British Medical Journal, 2009, 338, a3172-a3172.	2.3	579

#	Article	IF	CITATIONS
19	Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Antiâ€HIV Drugs (D:A:D) Study. Journal of Infectious Diseases, 2010, 201, 318-330.	4.0	575
20	British HIV Association guidelines for the treatment of HIVâ€lâ€infected adults with antiretroviral therapy 2008. HIV Medicine, 2008, 9, 563-608.	2.2	530
21	Increases in Adult Life Expectancy in Rural South Africa: Valuing the Scale-Up of HIV Treatment. Science, 2013, 339, 961-965.	12.6	496
22	Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naÃ <sup>-</sup> ve patients. Aids, 2000, 14, 499-507.	2.2	483
23	Incidence and Risk Factors for New-Onset Diabetes in HIV-Infected Patients. Diabetes Care, 2008, 31, 1224-1229.	8.6	448
24	AIDS across Europe, 1994â $\in$ "98: the EuroSIDA study. Lancet, The, 2000, 356, 291-296.	13.7	431
25	Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet, The, 2001, 357, 592-598.	13.7	403
26	Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. Aids, 2010, 24, 1537-1548.	2.2	381
27	Late presentation of HIV infection: a consensus definition. HIV Medicine, 2011, 12, 61-64.	2.2	378
28	Major Clinical Outcomes in Antiretroviral Therapy (ART)–Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study. Journal of Infectious Diseases, 2008, 197, 1133-1144.	4.0	364
29	Influence of Hepatitis C Virus Infection on HIVâ€1 Disease Progression and Response to Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2005, 192, 992-1002.	4.0	362
30	The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. Aids, 2010, 24, 123-137.	2.2	360
31	A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. New England Journal of Medicine, 2021, 384, 905-914.	27.0	357
32	ASSOCIATION BETWEEN SERUM ALBUMIN AND MORTALITY FROM CARDIOVASCULAR DISEASE, CANCER, AND OTHER CAUSES. Lancet, The, 1989, 334, 1434-1436.	13.7	355
33	Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. Aids, 2010, 24, 1667-1678.	2.2	353
34	Projected life expectancy of people with HIV according to timing of diagnosis. Aids, 2012, 26, 335-343.	2.2	350
35	Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infectious Diseases, The, 2011, 11, 363-371.	9.1	345
36	Interleukin-2 Therapy in Patients with HIV Infection. New England Journal of Medicine, 2009, 361, 1548-1559.	27.0	342

#	Article	IF	CITATIONS
37	HIV infection. Nature Reviews Disease Primers, 2015, 1, 15035.	30.5	340
38	Cardiovascular disease risk factors in HIV patientsassociation with antiretroviral therapy. Results from the DAD study. Aids, 2003, 17, 1179-93.	2.2	335
39	Cohort Profile: Africa Centre Demographic Information System (ACDIS) and population-based HIV survey. International Journal of Epidemiology, 2008, 37, 956-962.	1.9	324
40	HIV Treatment as Prevention: Systematic Comparison of Mathematical Models of the Potential Impact of Antiretroviral Therapy on HIV Incidence in South Africa. PLoS Medicine, 2012, 9, e1001245.	8.4	324
41	Life expectancy living with HIV. Current Opinion in Infectious Diseases, 2013, 26, 17-25.	3.1	317
42	Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. Aids, 2013, 27, 973-979.	2.2	315
43	Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 491-501.	2.8	309
44	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet, The, 2004, 364, 51-62.	13.7	303
45	The use of the Framingham equation to predict myocardial infarctions in HIVâ€infected patients: comparison with observed events in the D:A:D Study. HIV Medicine, 2006, 7, 218-230.	2.2	296
46	Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models. Lancet HIV,the, 2020, 7, e629-e640.	4.7	295
47	Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. Aids, 2001, 15, 1261-1268.	2.2	286
48	Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ: British Medical Journal, 2011, 343, d6016-d6016.	2.3	282
49	Association Between Antiretroviral Exposure and Renal Impairment Among HIV-Positive Persons With Normal Baseline Renal Function: the D:A:D Studya. Journal of Infectious Diseases, 2013, 207, 1359-1369.	4.0	271
50	Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. Aids, 2007, 21, 1185-1197.	2.2	264
51	The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan. Antiviral Therapy, 2000, 5, 41-48.	1.0	263
52	How independent are "independent―effects? relative risk estimation when correlated exposures are measured imprecisely. Journal of Clinical Epidemiology, 1991, 44, 1223-1231.	5.0	258
53	Recreational drug use, polydrug use, and sexual behaviour in HIV-diagnosed men who have sex with men in the UK: results from the cross-sectional ASTRA study. Lancet HIV,the, 2014, 1, e22-e31.	4.7	254
54	Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population. Lancet HIV,the, 2014, 1, e32-e40.	4.7	245

#	Article	IF	CITATIONS
55	HIV Viral Load Response to Antiretroviral Therapy According to the Baseline CD4 Cell Count and Viral Load. JAMA - Journal of the American Medical Association, 2001, 286, 2560.	7.4	238
56	The role of HIV in serious diseases other than AIDS. Aids, 2008, 22, 2409-2418.	2.2	227
57	Regression Discontinuity Designs in Epidemiology. Epidemiology, 2014, 25, 729-737.	2.7	224
58	Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet, The, 2007, 370, 407-413.	13.7	217
59	Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. Lancet Infectious Diseases, The, 2011, 11, 942-951.	9.1	213
60	HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet, The, 2006, 368, 451-458.	13.7	209
61	HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. Aids, 2008, 22, 2143-2153.	2.2	207
62	Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. Lancet, The, 1999, 353, 1293-1298.	13.7	206
63	Interventions to improve adherence to antiretroviral therapy. Aids, 2014, 28, S187-S204.	2.2	199
64	Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America. Clinical Infectious Diseases, 2005, 41, 1772-1782.	5.8	197
65	Increased HIV Incidence in Men Who Have Sex with Men Despite High Levels of ART-Induced Viral Suppression: Analysis of an Extensively Documented Epidemic. PLoS ONE, 2013, 8, e55312.	2.5	197
66	Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. Aids, 2000, 14, 2857-2867.	2.2	194
67	Late presenters in the era of highly active antiretroviral therapy. Aids, 2004, 18, 2145-2151.	2.2	194
68	Inferior Clinical Outcome of the CD4+ Cell Count–Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV RNA Levels during Follow-up. Journal of Infectious Diseases, 2008, 197, 1145-1155.	4.0	191
69	Interruption of Antiretroviral Therapy and Risk of Cardiovascular Disease in Persons with HIV-1 Infection: Exploratory Analyses from the SMART Trial. Antiviral Therapy, 2008, 13, 177-188.	1.0	191
70	Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. The Lancet Global Health, 2014, 2, e23-e34.	6.3	188
71	Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. Aids, 2001, 15, 185-194.	2.2	187
72	Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. Lancet HIV,the, 2018, 5, e116-e125.	4.7	187

#	Article	IF	CITATIONS
73	Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Medicine, 2003, 4, 255-262.	2.2	181
74	Regression discontinuity designs are underutilized in medicine, epidemiology, and public health: a review of current and best practice. Journal of Clinical Epidemiology, 2015, 68, 132-143.	5.0	181
75	Time From Human Immunodeficiency Virus Seroconversion to Reaching CD4+ Cell Count Thresholds <200, <350, and <500 Cells/mm3: Assessment of Need Following Changes in Treatment Guidelines. Clinical Infectious Diseases, 2011, 53, 817-825.	5.8	180
76	An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. European Journal of Preventive Cardiology, 2016, 23, 214-223.	1.8	180
77	Localized spatial clustering of HIV infections in a widely disseminated rural South African epidemic. International Journal of Epidemiology, 2009, 38, 1008-1016.	1.9	173
78	Diagnosed and undiagnosed HIVâ€infected populations in Europe. HIV Medicine, 2008, 9, 6-12.	2.2	171
79	Changes in the incidence and predictors of human immunodeficiency virus–associated dementia in the era of highly active antiretroviral therapy. Annals of Neurology, 2008, 63, 213-221.	5.3	167
80	A Comparison of Sclerotherapy with Staple Transection of the Esophagus for the Emergency Control of Bleeding from Esophageal Varices. New England Journal of Medicine, 1989, 321, 857-862.	27.0	166
81	Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ: British Medical Journal, 2005, 331, 1368.	2.3	163
82	Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet, The, 2008, 371, 1443-1451.	13.7	158
83	Poly drug use, chemsex drug use, and associations with sexual risk behaviour in HIV-negative men who have sex with men attending sexual health clinics. International Journal of Drug Policy, 2017, 43, 33-43.	3.3	157
84	Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. Lancet HIV,the, 2018, 5, e291-e300.	4.7	155
85	Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. Aids, 2004, 18, 51-58.	2.2	154
86	Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy. PLoS ONE, 2016, 11, e0155100.	2.5	150
87	British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Medicine, 2012, 13, 1-6.	2.2	149
88	Human herpesviruses 6 and 7 as potential pathogens after liver transplant: Prospective comparison with the effect of cytomegalovirus. Journal of Medical Virology, 1999, 59, 496-501.	5.0	146
89	Factors Associated With Plasma IL-6 Levels During HIV Infection. Journal of Infectious Diseases, 2015, 212, 585-595.	4.0	145
90	Adult mortality and antiretroviral treatment roll-out in rural KwaZulu-Natal, South Africa. Bulletin of the World Health Organization, 2009, 87, 754-762.	3.3	145

#	Article	IF	CITATIONS
91	Cirrhotics with variceal hemorrhage: The importance of the time interval between admission and the start of analysis for survival and rebleeding rates. Hepatology, 1989, 9, 801-807.	7.3	144
92	Plasma HIV-1 RNA Detection Below 50 Copies/mL and Risk of Virologic Rebound in Patients Receiving Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2012, 54, 724-732.	5.8	144
93	Smoking as "independent" risk factor for suicide: illustration of an artifact from observational epidemiology?. Lancet, The, 1992, 340, 709-712.	13.7	142
94	Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. Aids, 1998, 12, 2161-2167.	2.2	142
95	Sustainable HIV treatment in Africa through viral-load-informed differentiated care. Nature, 2015, 528, S68-S76.	27.8	141
96	Activation and Coagulation Biomarkers Are Independent Predictors of the Development of Opportunistic Disease in Patients with HIV Infection. Journal of Infectious Diseases, 2009, 200, 973-983.	4.0	140
97	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clinical Infectious Diseases, 2014, 58, 1312-1321.	5.8	140
98	Virologic, Immunologic, and Clinical Response to Highly Active Antiretroviral Therapy: the Gender Issue Revisited. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 32, 452-461.	2.1	136
99	Dramatic increase in HIV prevalence after scale-up of antiretroviral treatment. Aids, 2013, 27, 2301-2305.	2.2	134
100	Effect of concurrent sexual partnerships on rate of new HIV infections in a high-prevalence, rural South African population: a cohort study. Lancet, The, 2011, 378, 247-255.	13.7	133
101	The changing pattern of Kaposi sarcoma in patients with HIV, 1994–2003. Cancer, 2004, 100, 2644-2654.	4.1	132
102	The Coding Causes of Death in HIV (CoDe) Project. Epidemiology, 2011, 22, 516-523.	2.7	129
103	Factors Influencing Increases in CD4 Cell Counts of HIVâ€Positive Persons Receiving Longâ€Term Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2004, 190, 1860-1868.	4.0	127
104	HIV and Aging — Preparing for the Challenges Ahead. New England Journal of Medicine, 2012, 366, 1270-1273.	27.0	127
105	The Changing Incidence of AIDS Events in Patients Receiving Highly Active Antiretroviral Therapy. Archives of Internal Medicine, 2005, 165, 416.	3.8	124
106	Elimination of HIV in South Africa through Expanded Access to Antiretroviral Therapy: A Model Comparison Study. PLoS Medicine, 2013, 10, e1001534.	8.4	124
107	Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. Aids, 1999, 13, 951-956.	2.2	122
108	Shortâ€ŧerm weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the <scp>D</scp> : <scp>A</scp> : <scp>D</scp> study. HIV Medicine, 2016, 17, 255-268.	2.2	122

#	Article	IF	CITATIONS
109	Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. Aids, 1999, 13, 2075-2082.	2.2	121
110	Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. Aids, 2005, 19, 487-494.	2.2	120
111	Risk for Opportunistic Disease and Death after Reinitiating Continuous Antiretroviral Therapy in Patients with HIV Previously Receiving Episodic Therapy. Annals of Internal Medicine, 2008, 149, 289.	3.9	118
112	Production of βâ€Chemokines in Human Immunodeficiency Virus (HIV) Infection: Evidence that High Levels of Macrophage Inflammatory Proteinâ€1β Are Associated with a Decreased Risk of HIV Disease Progression. Journal of Infectious Diseases, 1998, 177, 331-336.	4.0	116
113	A Clinically Prognostic Scoring System for Patients Receiving Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study. Journal of Infectious Diseases, 2002, 185, 178-187.	4.0	116
114	Concentrated HIV subepidemics in generalized epidemic settings. Current Opinion in HIV and AIDS, 2014, 9, 115-125.	3.8	114
115	Updated European Recommendations for the Clinical Use of HIV Drug Resistance Testing. Antiviral Therapy, 2004, 9, 829-848.	1.0	114
116	Impact of Therapeutic Immunization on HIVâ€1 Viremia after Discontinuation of Antiretroviral Therapy Initiated during Acute Infection. Journal of Infectious Diseases, 2005, 192, 607-617.	4.0	111
117	CD8+, CD38+ Lymphocyte Percent. Journal of Acquired Immune Deficiency Syndromes, 1997, 14, 158-162.	0.3	111
118	Virological response to protease inhibitor therapy in an HIV clinic cohort. Aids, 1999, 13, 367-373.	2.2	109
119	Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?. Aids, 2005, 19, 2117-2125.	2.2	109
120	Mass HIV Treatment and Sex Disparities in Life Expectancy: Demographic Surveillance in Rural South Africa. PLoS Medicine, 2015, 12, e1001905.	8.4	109
121	Reduced bone mineral density in HIV-positive individuals. Aids, 2001, 15, 1731-1733.	2.2	107
122	Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. Aids, 2002, 16, 1967-1969.	2.2	107
123	HIV self-testing among female sex workers in Zambia: A cluster randomized controlled trial. PLoS Medicine, 2017, 14, e1002442.	8.4	107
124	Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial. Trials, 2013, 14, 230.	1.6	105
125	Predictors of Hypertension and Changes of Blood Pressure in HIV-Infected Patients. Antiviral Therapy, 2005, 10, 811-823.	1.0	103
126	Leukocyte Count and Risk of Major Coronary Heart Disease Events. American Journal of Epidemiology, 1992, 136, 59-70.	3.4	102

8

#	Article	IF	CITATIONS
127	Declines in HIV incidence among men and women in a South African population-based cohort. Nature Communications, 2019, 10, 5482.	12.8	102
128	Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet, The, 2011, 377, 1580-1587.	13.7	101
129	British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.). HIV Medicine, 2014, 15, 1-6.	2.2	101
130	Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clinical Trials, 2013, 10, S5-S36.	1.6	100
131	Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. BMC Medicine, 2016, 14, 61.	5.5	100
132	Bias in relative odds estimation owing to imprecise measurement of correlated exposures. Statistics in Medicine, 1992, 11, 953-961.	1.6	99
133	Virological rebound after suppression on highly active antiretroviral therapy. Aids, 2003, 17, 1741-1751.	2.2	99
134	Direct provision versus facility collection of HIV self-tests among female sex workers in Uganda: A cluster-randomized controlled health systems trial. PLoS Medicine, 2017, 14, e1002458.	8.4	99
135	Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antiviral Therapy, 2008, 13, 177-87.	1.0	95
136	Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV Infection. Journal of Infectious Diseases, 2016, 214, 408-416.	4.0	94
137	Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. Aids, 2002, 16, 53-61.	2.2	93
138	Short Stature, Lung Function and Risk of a Heart Attack. International Journal of Epidemiology, 1989, 18, 602-606.	1.9	92
139	In A Study Of A Population Cohort In South Africa, HIV Patients On Antiretrovirals Had Nearly Full Recovery Of Employment. Health Affairs, 2012, 31, 1459-1469.	5.2	92
140	Persistence of HIV-1 Transmitted Drug Resistance Mutations. Journal of Infectious Diseases, 2013, 208, 1459-1463.	4.0	92
141	The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥200 Cells/µL in the Post–Combination Antiretroviral Therapy Era. Clinical Infectious Diseases, 2013, 57, 1038-1047.	5.8	92
142	Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub–Saharan Africa. Journal of Infectious Diseases, 2017, 215, 1362-1365.	4.0	90
143	Plasma Albumin and Incident Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 473-482.	2.4	90
144	Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events. Aids, 2013, 27, 407-415.	2.2	89

#	Article	IF	CITATIONS
145	Virologic and Immunologic Response to Regimens Containing Nevirapine or Efavirenz in Combination with 2 Nucleoside Analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) Study. Journal of Infectious Diseases, 2002, 185, 1062-1069.	4.0	88
146	HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. BMJ: British Medical Journal, 1994, 309, 1537-1542.	2.3	88
147	Category of exposure to HIV and age in the progression to AIDS: longitudinal study of 1199 people with known dates of seroconversion. BMJ: British Medical Journal, 1996, 313, 583-586.	2.3	88
148	When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study. Aids, 2001, 15, 983-990.	2.2	87
149	Current CD4 Cell Count and the Shortâ€Term Risk of AIDS and Death before the Availability of Effective Antiretroviral Therapy in HIVâ€Infected Children and Adults. Journal of Infectious Diseases, 2008, 197, 398-404.	4.0	87
150	The natural history of human immunodeficiency virus infection in a haemophilic cohort. British Journal of Haematology, 1989, 73, 228-234.	2.5	86
151	Dual Resistance to Zidovudine and Lamivudine in Patients Treated with Zidovudine‣amivudine Combination Therapy: Association with Therapy Failure. Journal of Infectious Diseases, 1998, 177, 1521-1532.	4.0	86
152	Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. Aids, 2007, 21, 721-732.	2.2	85
153	HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. European Journal of Neurology, 2011, 18, 527-534.	3.3	85
154	Survival differences in European patients with AIDS, 1979-89. BMJ: British Medical Journal, 1994, 308, 1068-7103.	2.3	85
155	Disease progression and survival in HIV-1-infected Africans in London. Aids, 1998, 12, 1203-1209.	2.2	84
156	Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study. Lancet HIV,the, 2019, 6, e116-e127.	4.7	84
157	Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μL in Europe and North America: a pooled cohort observational study. Lancet, The, 2010, 376, 340-345.	13.7	82
158	CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. Haematologica, 2009, 94, 875-880.	3.5	81
159	Why do people living with HIV not initiate treatment? A systematic review of qualitative evidence from low- and middle-income countries. Social Science and Medicine, 2018, 213, 72-84.	3.8	81
160	Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation. Lancet Infectious Diseases, The, 2018, 18, 85-94.	9.1	80
161	Determinants of Virological Failure after Successful Viral Load Suppression in First-Line Highly Active Antiretroviral Therapy. Antiviral Therapy, 2008, 13, 927-936.	1.0	80
162	Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Aids, 2000, 14, 1545-1552.	2.2	79

#	Article	IF	CITATIONS
163	Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. Aids, 2006, 20, 67-71.	2.2	79
164	Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings. Aids, 2011, 25, 843-850.	2.2	79
165	Estimating HIV Incidence, Time to Diagnosis, and the Undiagnosed HIV Epidemic Using Routine Surveillance Data. Epidemiology, 2015, 26, 653-660.	2.7	79
166	The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection. Aids, 1998, 12, 1639-1643.	2.2	78
167	British HIV Association guidelines for the treatment of <scp>HIV</scp> â€lâ€positive adults with antiretroviral therapy 2015. HIV Medicine, 2016, 17, s2-s104.	2.2	78
168	Targeted combination prevention to support female sex workers in Zimbabwe accessing and adhering to antiretrovirals for treatment and prevention of HIV (SAPPH-IRe): a cluster-randomised trial. Lancet HIV,the, 2018, 5, e417-e426.	4.7	78
169	Changes Over Time in Risk of Initial Virological Failure of Combination Antiretroviral Therapy. Archives of Internal Medicine, 2006, 166, 521.	3.8	77
170	High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. Aids, 2010, 24, 427-435.	2.2	76
171	Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. Aids, 2007, 21, 1717-1721.	2.2	75
172	Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples. American Journal of Epidemiology, 2019, 188, 1569-1577.	3.4	75
173	Ageing with HIV in South Africa. Aids, 2011, 25, 1665-1667.	2.2	73
174	Factors Associated With Adherence Amongst 5295 People Receiving Antiretroviral Therapy as Part of an International Trial. Journal of Infectious Diseases, 2013, 208, 40-49.	4.0	72
175	Late diagnosis in the HAART era: proposed common definitions and associations with mortality. Aids, 2010, 24, 723-727.	2.2	72
176	Declaring independence: why we should be cautious Journal of Epidemiology and Community Health, 1990, 44, 257-258.	3.7	71
177	Factors Associated with the Development of Opportunistic Infections in HIVâ€1–Infected Adults with High CD4+Cell Counts: A EuroSIDA Study. Journal of Infectious Diseases, 2006, 194, 633-641.	4.0	70
178	Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002–2009. Aids, 2013, 27, 803-813.	2.2	70
179	Changes in chemsex and sexual behaviour over time, among a cohort of MSM in London and Brighton: Findings from the AURAH2 study. International Journal of Drug Policy, 2019, 68, 54-61.	3.3	70
180	Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. International Journal of Epidemiology, 1997, 26, 400-407.	1.9	69

#	Article	IF	CITATIONS
181	Reasons for Stopping Antiretrovirals Used in an Initial Highly Active Antiretroviral Regimen: Increased Incidence of Stopping due to Toxicity or Patient/Physician Choice in Patients with Hepatitis C Coinfection. AIDS Research and Human Retroviruses, 2005, 21, 743-752.	1.1	69
182	Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. BMJ: British Medical Journal, 2005, 330, 695.	2.3	69
183	Impact of early initiation versus national standard of care of antiretroviral therapy in Swaziland's public sector health system: study protocol for a stepped-wedge randomized trial. Trials, 2017, 18, 383.	1.6	69
184	Spectrum of disease in Africans with AIDS in London. Aids, 1996, 10, 1563-1569.	2.2	68
185	The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. Aids, 2003, 17, 963-969.	2.2	68
186	Human Immunodeficiency Virus (HIV) Antibody Avidity Testing To Identify Recent Infection in Newly Diagnosed HIV Type 1 (HIV-1)-Seropositive Persons Infected with Diverse HIV-1 Subtypes. Journal of Clinical Microbiology, 2007, 45, 415-420.	3.9	68
187	When should antiretroviral therapy for HIV be started?. BMJ: British Medical Journal, 2007, 334, 76-78.	2.3	68
188	Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Medicine, 2007, 8, 96-104.	2.2	68
189	Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. BMC Infectious Diseases, 2013, 13, 471.	2.9	68
190	Socioeconomic status and treatment outcomes for individuals with HIV on antiretroviral treatment in the UK: cross-sectional and longitudinal analyses. Lancet Public Health, The, 2016, 1, e26-e36.	10.0	68
191	Constructing the cascade of HIV care. Current Opinion in HIV and AIDS, 2016, 11, 102-108.	3.8	65
192	Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial. Open Forum Infectious Diseases, 2017, 4, ofx262.	0.9	65
193	Changes in recreational drug use, drug use associated with chemsex, and HIV-related behaviours, among HIV-negative men who have sex with men in London and Brighton, 2013–2016. Sexually Transmitted Infections, 2018, 94, 494-501.	1.9	65
194	Prognostic Importance of Anaemia in HIV Type-1-Infected Patients Starting Antiretroviral Therapy: Collaborative Analysis of Prospective Cohort Studies. Antiviral Therapy, 2008, 13, 959-967.	1.0	65
195	The design of prospective epidemiological studies: More subjects or better measurements?. Journal of Clinical Epidemiology, 1993, 46, 1203-1211.	5.0	64
196	Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. International Journal of Epidemiology, 2002, 31, 951-958.	1.9	64
197	Access to Antiretroviral Treatment, Incidence of Sustained Therapy Interruptions, and Risk of Clinical Events According to Sex. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 184-190.	2.1	64
198	Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. Journal of Antimicrobial Chemotherapy, 2007, 59, 517-524.	3.0	64

#	Article	IF	CITATIONS
199	Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. Aids, 2008, 22, 2279-2289.	2.2	64
200	Transmission of Drug Resistant HIV and Its Potential Impact on Mortality and Treatment Outcomes in Resource-Limited Settings. Journal of Infectious Diseases, 2013, 207, S57-S62.	4.0	64
201	Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. Aids, 2001, 15, 2385-2395.	2.2	61
202	Gender and Clinical Outcomes After Starting Highly Active Antiretroviral Treatment: A Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 197-202.	2.1	61
203	Economics of antiretroviral treatment vs. circumcision for HIV prevention. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 21271-21276.	7.1	61
204	Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa. Aids, 2013, 27, 2943-2951.	2.2	61
205	Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study. Lancet HIV,the, 2018, 5, e146-e154.	4.7	61
206	Effect of population viral load on prospective HIV incidence in a hyperendemic rural African community. Science Translational Medicine, 2017, 9, .	12.4	60
207	Treatment eligibility and retention in clinical HIV care: A regression discontinuity study in South Africa. PLoS Medicine, 2017, 14, e1002463.	8.4	60
208	Incidence rate estimation, periodic testing and the limitations of the mid-point imputation approach. International Journal of Epidemiology, 2018, 47, 236-245.	1.9	60
209	The impact and costâ€effectiveness of communityâ€based <scp>HIV</scp> selfâ€testing in subâ€Saharan Africa: a health economic and modelling analysis. Journal of the International AIDS Society, 2019, 22, e25243.	3.0	60
210	Factors Associated with D-Dimer Levels in HIV-Infected Individuals. PLoS ONE, 2014, 9, e90978.	2.5	60
211	Estimating HIVâ€1 Drug Resistance in Antiretroviralâ€Treated Individuals in the United Kingdom. Journal of Infectious Diseases, 2005, 192, 967-973.	4.0	59
212	Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Lancet, The, 2007, 370, 1923-1928.	13.7	59
213	From HIV infection to therapeutic response: a population-based longitudinal HIV cascade-of-care study in KwaZulu-Natal, South Africa. Lancet HIV,the, 2017, 4, e223-e230.	4.7	59
214	Changing Knowledge and Attitudes Towards HIV Treatment-as-Prevention and "Undetectable = Untransmittable― A Systematic Review. AIDS and Behavior, 2021, 25, 4209-4224.	2.7	59
215	A sex comparison of rates of new AIDS-defining disease and death in 2554 AIDS cases. Aids, 1994, 8, 831-836.	2.2	58
216	Gender Differences in Virologic Response to Treatment in an HIV-Positive Population: A Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 159-163.	2.1	58

#	Article	IF	CITATIONS
217	Impact of Antiretroviral Therapy on Tuberculosis Incidence Among HIV-Positive Patients in High-Income Countries. Clinical Infectious Diseases, 2012, 54, 1364-1372.	5.8	58
218	Minimal Cognitive Impairment in UK HIV-Positive Men Who Have Sex With Men. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 120-127.	2.1	58
219	Regional Differences in Use of Antiretroviral Agents and Primary Prophylaxis in 3122 European HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes, 1997, 16, 153-160.	0.3	58
220	Clinically Validated Genotype Analysis: Guiding Principles and Statistical Concerns. Antiviral Therapy, 2004, 9, 465-478.	1.0	58
221	Cigarette Smoking as a Potential Cause of Cervical Cancer: Has Confounding been Controlled?. International Journal of Epidemiology, 1994, 23, 42-49.	1.9	57
222	Assessment of the Potential Impact and Cost-effectiveness of Self-Testing for HIV in Low-Income Countries. Journal of Infectious Diseases, 2015, 212, 570-577.	4.0	57
223	The CD4 lymphocyte count and risk of clinical progression. Current Opinion in HIV and AIDS, 2006, 1, 43-49.	3.8	56
224	Rate of Accumulation of Thymidine Analogue Mutations in Patients Continuing to Receive Virologically Failing Regimens Containing Zidovudine or Stavudine: Implications for Antiretroviral Therapy Programs in Resource‣imited Settings. Journal of Infectious Diseases, 2009, 200, 687-697.	4.0	56
225	Low-Frequency K103N Strengthens the Impact of Transmitted Drug Resistance on Virologic Responses to First-Line Efavirenz or Nevirapine-Based Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, 569-573.	2.1	56
226	Prevention of HIV-1 Infection with Antiretroviral Therapy. New England Journal of Medicine, 2011, 365, 1934-1935.	27.0	56
227	Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. Journal of Antimicrobial Chemotherapy, 2011, 66, 1886-1896.	3.0	56
228	Does ART prevent HIV transmission among MSM?. Aids, 2012, 26, 2267-2273.	2.2	56
229	Socioeconomic status and response to antiretroviral therapy in high-income countries. Aids, 2016, 30, 1147-1161.	2.2	56
230	CD8 lymphocyte counts and serum immunoglobulin A levels early in HIV infection as predictors of CD4 lymphocyte depletion during 8 years of follow-up. Aids, 1993, 7, 975-980.	2.2	55
231	Predictors of Virological Outcome and Safety in Primary HIV Type 1-Infected Patients Initiating Quadruple Antiretroviral Therapy: QUEST GW PROB3005. Clinical Infectious Diseases, 2007, 45, 381-390.	5.8	55
232	Thymidine Analogue Mutation Profiles: Factors Associated with Acquiring Specific Profiles and their Impact on the Virological Response to Therapy. Antiviral Therapy, 2005, 10, 791-802.	1.0	55
233	Disease progression and survival following specific AIDS-defining conditions. Aids, 1998, 12, 1007-1013.	2.2	54
234	Lymphocyte activation in HIV-1 infection. I. Predominant proliferative defects among CD45RO+ cells of the CD4 and CD8 lineages. Aids, 1993, 7, 613-624.	2.2	53

#	Article	IF	CITATIONS
235	Course of Viral Load Throughout HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 23, 172-177.	2.1	53
236	When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. Aids, 2003, 17, 1863-1869.	2.2	53
237	Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. Aids, 2001, 15, 2379-2384.	2.2	52
238	Association of Virus Load, CD4 Cell Count, and Treatment with Clinical Progression in Human Immunodeficiency Virus–Infected Patients with Very Low CD4 Cell Counts. Journal of Infectious Diseases, 2002, 186, 189-197.	4.0	52
239	Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. Lancet HIV,the, 2015, 2, e335-e343.	4.7	52
240	HIV Drug Susceptibility and Treatment Response to Mega-Haart Regimen in Patients from the Frankfurt HIV Cohort. Antiviral Therapy, 2000, 5, 49-55.	1.0	52
241	HIV-1 Subtypes and Response to Combination Antiretroviral Therapy in Europe. Antiviral Therapy, 2006, 11, 707-716.	1.0	52
242	Associations between immune depression and cardiovascular events in HIV infection. Aids, 2013, 27, 2735-2748.	2.2	51
243	Natural immunity and HIV disease progression. Aids, 1999, 13, 557-563.	2.2	50
244	Antiretroviral Drug Resistance in HIVâ€1â€Infected Patients with Lowâ€Level Viremia. Journal of Infectious Diseases, 2010, 201, 1303-1307.	4.0	50
245	Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. Aids, 2016, 30, 1731-1743.	2.2	50
246	Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIVâ€Positive Participants in the START (Strategic Timing of Antiretroviral) Tj ETQq0 0	0 r&BT /0	vertoock 10 Tf
247	Intimate partner violence, depression, and sexual behaviour among gay, bisexual and other men who have sex with men in the PROUD trial. BMC Public Health, 2019, 19, 431.	2.9	50
248	Survival after diagnosis of AIDS: a prospective observational study of 2625 patients. BMJ: British Medical Journal, 1997, 314, 409-409.	2.3	50
249	Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antiviral Therapy, 2008, 13, 959-67.	1.0	50
250	Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM. Aids, 2015, 29, 1855-1862.	2.2	49
251	Staging system for clinical AIDS patients. Lancet, The, 1995, 346, 12-17.	13.7	48
252	The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. Aids, 2001, 15, 201-209.	2.2	48

#	Article	IF	CITATIONS
253	Long-term trends in adherence to antiretroviral therapy from start of HAART. Aids, 2010, 24, 1153-1162.	2.2	48
254	Update on World Health Organization HIV Drug Resistance Prevention and Assessment Strategy: 2004-2011. Clinical Infectious Diseases, 2012, 54, S245-S249.	5.8	48
255	Rate of CD4 Decline and HIV-RNA Change Following HIV Seroconversion in Men Who Have Sex With Men. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 441-446.	2.1	48
256	Increased losses of CD4+CD45RA+ cells in late stages of HIV infection is related to increased risk of death. Aids, 1997, 11, 1479-1485.	2.2	47
257	Interactions between ?-herpesviruses and human immunodeficiency virus in vivo: Evidence for increased human immunodeficiency viral load in the presence of human herpesvirus 6. , 1999, 57, 278-282.		47
258	Viral Suppression Following Switch to Second-line Antiretroviral Therapy: Associations With Nucleoside Reverse Transcriptase Inhibitor Resistance and Subtherapeutic Drug Concentrations Prior to Switch. Journal of Infectious Diseases, 2014, 209, 711-720.	4.0	47
259	Projected Lifetime Healthcare Costs Associated with HIV Infection. PLoS ONE, 2015, 10, e0125018.	2.5	47
260	Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study. Lancet HIV,the, 2017, 4, e295-e302.	4.7	47
261	Non-Disclosure of HIV Status and Associations with Psychological Factors, ART Non-Adherence, and Viral Load Non-Suppression Among People Living with HIV in the UK. AIDS and Behavior, 2017, 21, 184-195.	2.7	47
262	The Impact of the New WHO Antiretroviral Treatment Guidelines on HIV Epidemic Dynamics and Cost in South Africa. PLoS ONE, 2011, 6, e21919.	2.5	47
263	The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. Aids, 1999, 13, 1255-1261.	2.2	46
264	Interruption of Highly Active Antiretroviral Therapy in HIV Clinical Practice. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 38, 407-416.	2.1	46
265	Transmitted Drug Resistant HIV-1 and Association With Virologic and CD4 Cell Count Response to Combination Antiretroviral Therapy in the EuroSIDA Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 48, 324-333.	2.1	46
266	Assessment of epidemic projections using recent HIV survey data in South Africa: a validation analysis of ten mathematical models of HIV epidemiology in the antiretroviral therapy era. The Lancet Global Health, 2015, 3, e598-e608.	6.3	46
267	Low Production of Interferon Î <sup>3</sup> Is Related to Disease Progression in HIV Infection: Evidence from a Cohort of 347 HIV-Infected Individuals. AIDS Research and Human Retroviruses, 1997, 13, 1039-1046.	1.1	45
268	The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4–8 viral load. Aids, 2001, 15, 47-54.	2.2	45
269	Physical and Psychological Symptoms and Risk of Virologic Rebound Among Patients With Virologic Suppression on Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 500-505.	2.1	45
270	Predicted levels of HIV drug resistance. Aids, 2014, 28, S15-S23.	2.2	45

#	Article	IF	CITATIONS
271	Higher rates of tripleâ€elass virological failure in perinatally <scp>HIV</scp> â€infected teenagers compared with heterosexually infected young adults in Europe. HIV Medicine, 2017, 18, 171-180.	2.2	45
272	Correlation without a cause: an epidemiological odyssey. International Journal of Epidemiology, 2020, 49, 4-14.	1.9	45
273	Immunodeficiency and the Risk of Death in HIV Infection. JAMA - Journal of the American Medical Association, 1992, 268, 2662.	7.4	44
274	Course of Viral Load Throughout HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 23, 172-177.	2.1	44
275	Temporal Trends in Postseroconversion CD4 Cell Count and HIV Load: The Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985–2002. Journal of Infectious Diseases, 2007, 195, 525-534.	4.0	44
276	Haemoglobin and albumin as markers of HIV disease progression in the highly active antiretrovial therapy era: relationships with gender. HIV Medicine, 2007, 8, 38-45.	2.2	44
277	Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ, The, 2012, 345, e5253-e5253.	6.0	44
278	Increased risk of cardiovascular disease ( <scp>CVD</scp> ) with age in <scp>HIV</scp> â€positive men: a comparison of the <scp>D</scp> : <scp>A</scp> : <scp>D CVD</scp> risk equation and general population <scp>CVD</scp> risk equation and general population	2.2	44
279	Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models. The Lancet Global Health, 2014, 2, e35-e43.	6.3	44
280	Use of antiretroviral therapy in households and risk of HIV acquisition in rural KwaZulu-Natal, South Africa, 2004–12: a prospective cohort study. The Lancet Global Health, 2014, 2, e209-e215.	6.3	44
281	Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial. Lancet HIV,the, 2017, 4, e105-e112.	4.7	44
282	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. Clinical Infectious Diseases, 2017, 65, 1316-1326.	5.8	44
283	Identifying â€~corridors of HIV transmission' in a severely affected rural South African population: a case for a shift toward targeted prevention strategies. International Journal of Epidemiology, 2018, 47, 537-549.	1.9	44
284	Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen. Aids, 2005, 19, 319-30.	2.2	44
285	Human Immunodeficiency Virus Rebound after Suppression to <400 Copies/mL during Initial Highly Active Antiretroviral Therapy Regimens, according to Prior Nucleoside Experience and Duration of Suppression. Journal of Infectious Diseases, 2002, 186, 1086-1091.	4.0	43
286	Outcomes Following Virological Failure and Predictors of Switching to Second-line Antiretroviral Therapy in a South African Treatment Program. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, 370-380.	2.1	43
287	During Stably Suppressive Antiretroviral Therapy Integrated HIV-1 DNA Load in Peripheral Blood is Associated with the Frequency of CD8 Cells Expressing HLA-DR/DP/DQ. EBioMedicine, 2015, 2, 1153-1159.	6.1	43
288	Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. International Journal of Epidemiology, 2016, 45, 2038-2049.	1.9	43

#	Article	IF	CITATIONS
289	Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years. Archives of Internal Medicine, 2010, 170, 410-419.	3.8	42
290	Antiretroviral Drug-Related Liver Mortality Among HIV-Positive Persons in the Absence of Hepatitis B or C Virus Coinfection: The Data Collection on Adverse Events of Anti-HIV Drugs Study. Clinical Infectious Diseases, 2013, 56, 870-879.	5.8	42
291	The Contribution of Viral Genotype to Plasma Viral Set-Point in HIV Infection. PLoS Pathogens, 2014, 10, e1004112.	4.7	42
292	Life expectancy in men who have never smoked and those who have smoked continuously: 15 year follow up of large cohort of middle aged British men. BMJ: British Medical Journal, 1996, 313, 907-908.	2.3	42
293	The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load. Aids, 2000, 14, 2129-2136.	2.2	41
294	Success of Clinical Care for Human Immunodeficiency Virus Infection According to Demographic Group Among Sexually Infected Patients in a Routine Clinic Population, 1999 to 2004. Archives of Internal Medicine, 2007, 167, 692.	3.8	41
295	Survival following HIV infection of a cohort followed up from seroconversion in the UK. Aids, 2008, 22, 89-95.	2.2	41
296	Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infectious Diseases, The, 2012, 12, 119-127.	9.1	41
297	Predictors of <scp>CD</scp> 4 cell recovery following initiation of antiretroviral therapy among <scp>HIV</scp> â€1 positive patients with wellâ€estimated dates of seroconversion. HIV Medicine, 2018, 19, 184-194.	2.2	41
298	Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines. Lancet HIV,the, 2020, 7, e193-e200.	4.7	41
299	Modeling the epidemiological impact of the UNAIDS 2025 targets to end AIDS as a public health threat by 2030. PLoS Medicine, 2021, 18, e1003831.	8.4	41
300	Influence of Age on Rates of New AIDS-defining Diseases and Survival in 6546 AIDS Patients. Scandinavian Journal of Infectious Diseases, 1997, 29, 337-343.	1.5	40
301	Gender Differences in Virologic Response to Treatment in an HIV-Positive Population: A Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 159-163.	2.1	40
302	Regional Changes Over Time in Initial Virologic Response Rates to Combination Antiretroviral Therapy Across Europe. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 229-237.	2.1	40
303	Long-term financing needs for HIV control in sub-Saharan Africa in 2015–2050: a modelling study. BMJ Open, 2016, 6, e009656.	1.9	40
304	Risk of new AIDS diseases in people on triple therapy. Lancet, The, 1999, 353, 463.	13.7	39
305	Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?. Aids, 2002, 16, 615-618.	2.2	39
306	Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. Aids, 2006, 20, 1141-1150.	2.2	39

#	Article	IF	CITATIONS
307	The prevalence of hepatitis C virus (HCV) infection in HIVâ€positive individuals in the UK – trends in HCV testing and the impact of HCV on HIV treatment outcomes. Journal of Viral Hepatitis, 2010, 17, 569-577.	2.0	39
308	Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. Aids, 2011, 25, 1497-1504.	2.2	39
309	Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis. Lancet HIV,the, 2014, 1, e85-e93.	4.7	39
310	Changing HIV treatment eligibility under health system constraints in sub-Saharan Africa. Aids, 2016, 30, 2341-2350.	2.2	39
311	Condomless sex in HIV-diagnosed men who have sex with men in the UK: prevalence, correlates, and implications for HIV transmission. Sexually Transmitted Infections, 2017, 93, 590-598.	1.9	39
312	Simplifying switch to second-line antiretroviral therapy in sub Saharan Africa. Aids, 2019, 33, 1635-1644.	2.2	39
313	Prediction of progression to AIDS by analysis of CD4 lymphocyte counts in a haemophilic cohort. Aids, 1989, 3, 737-742.	2.2	38
314	Acquired Immunodeficiency Syndrome (AIDS) Risk in Recent and Long-standing Human Immunodeficiency Virus Type 1 (HIV-1)-infected Patients with Similar CD4 Lymphocyte Counts. American Journal of Epidemiology, 1993, 138, 870-878.	3.4	38
315	Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. Aids, 2007, 21, 1867-1875.	2.2	38
316	Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention?. Aids, 2009, 23, 2507-2515.	2.2	38
317	Body Mass Index and the Risk of Serious Non-AIDS Events and All-Cause Mortality in Treated HIV-Positive Individuals: D:A:D Cohort Analysis. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 579-588.	2.1	38
318	Integrating HIV services and other health services: AÂsystematic review and meta-analysis. PLoS Medicine, 2021, 18, e1003836.	8.4	38
319	Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. Aids, 2008, 22, 2187-2198.	2.2	37
320	Stability of antiretroviral regimens in patients with viral suppression. Aids, 2008, 22, 1039-1046.	2.2	37
321	HIV Treatment as Prevention: Issues in Economic Evaluation. PLoS Medicine, 2012, 9, e1001263.	8.4	37
322	What do we know about the cost–effectiveness of HIV preexposure prophylaxis, and is it affordable?. Current Opinion in HIV and AIDS, 2016, 11, 56-66.	3.8	37
323	Resistance Profiles in Patients with Viral Rebound on Potent Antiretroviral Therapy. Journal of Infectious Diseases, 2000, 181, 1143-1147.	4.0	36
324	Reasons for Stopping Antiretrovirals Used in an Initial Highly Active Antiretroviral Regimen: Increased Incidence of Stopping Due to Toxicity or Patient/Physician Choice in Patients with Hepatitis C Coinfection. AIDS Research and Human Retroviruses, 2005, 21, 527-536.	1.1	36

#	Article	IF	CITATIONS
325	CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997?2003. HIV Medicine, 2007, 8, 135-141.	2.2	36
326	Outcomes in the First Year after Initiation of First-Line Haart among Heterosexual Men and Women in the Uk Chic Study. Antiviral Therapy, 2011, 16, 805-814.	1.0	36
327	Participation Dynamics in Population-Based Longitudinal HIV Surveillance in Rural South Africa. PLoS ONE, 2015, 10, e0123345.	2.5	36
328	CD4 lymphocyte count as a determinant of the time from HIV seroconversion to AIDS and death from AIDS: evidence from the Italian Seroconversion Study. Aids, 1994, 8, 1299-1305.	2.2	35
329	The Molecular Epidemiology of Human Immunodeficiency Virus Type 1 in Six Cities in Britain and Ireland. Virology, 1997, 235, 166-177.	2.4	35
330	Plasma Viral Load Concentrations in Women and Men From Different Exposure Categories and With Known Duration of HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 25, 56-62.	2.1	35
331	The Rate of Viral Rebound after Attainment of an HIV Load <50 Copies/mL According to Specific Antiretroviral Drugs in Use: Results from a Multicenter Cohort Study. Journal of Infectious Diseases, 2005, 192, 1387-1397.	4.0	35
332	HBV or HCV Coinfections and Risk of Myocardial Infarction in HIV-Infected Individuals: The D:A:D Cohort Study. Antiviral Therapy, 2010, 15, 1077-1086.	1.0	35
333	Long-term exposure to combination antiretroviral therapy and risk of death from specific causes. Aids, 2012, 26, 315-323.	2.2	35
334	The HIV Epidemic in Sub-Saharan Africa is Aging: Evidence from the Demographic and Health Surveys in Sub-Saharan Africa. AIDS and Behavior, 2017, 21, 101-113.	2.7	35
335	Age, time living with diagnosed <scp>HIV</scp> infection, and selfâ€rated health. HIV Medicine, 2017, 18, 89-103.	2.2	35
336	Risk of Discontinuation of Nevirapine due to Toxicities in Antiretroviral-Naive and -Experienced HIV-Infected patients with High and Low CD4 <sup>+</sup> T-cell Counts. Antiviral Therapy, 2007, 12, 325-334.	1.0	35
337	Cervical Abnormality and Sexually Transmitted Disease Screening in Human Immunodeficiency Virus-Positive Women. Obstetrics and Gynecology, 1997, 89, 71-75.	2.4	34
338	Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens. Aids, 2000, 14, 1717-1720.	2.2	34
339	Causes of death in HIV infection. Aids, 2004, 18, 2333-2337.	2.2	34
340	â€~Test-and-treat': the end of the HIV epidemic?. Current Opinion in Infectious Diseases, 2011, 24, 19-26.	3.1	34
341	Renal Impairment and Cardiovascular Disease in HIV-Positive Individuals: The D:A:D Study. Journal of Infectious Diseases, 2016, 214, 1212-1220.	4.0	34
342	The impact of population dynamics on the population <scp>HIV</scp> care cascade: results from the <scp>ANRS</scp> 12249 Treatment as Prevention trial in rural KwaZuluâ€Natal (South Africa). Journal of the International AIDS Society, 2018, 21, e25128.	3.0	34

#	Article	IF	CITATIONS
343	A continuum of HIV care describing mortality and loss to follow-up: a longitudinal cohort study. Lancet HIV,the, 2018, 5, e301-e308.	4.7	34
344	Population-Based CD4 Counts in a Rural Area in South Africa with High HIV Prevalence and High Antiretroviral Treatment Coverage. PLoS ONE, 2013, 8, e70126.	2.5	34
345	Sample size requirements for prospective studies, with examples for coronary heart disease. Journal of Clinical Epidemiology, 1989, 42, 639-648.	5.0	33
346	The practical significance of potential biases in estimates of the AIDS incubation period distribution	2.2	33
347	The incidence of lymphoma in the UK haemophilia population between 1978 and 1999. Aids, 2002, 16, 1803-1807.	2.2	33
348	HIV in the UK 1980–2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy. HIV Medicine, 2007, 8, 536-546.	2.2	33
349	Use of a prescriptionâ€based measure of antiretroviral therapy adherence to predict viral rebound in HIVâ€infected individuals with viral suppression. HIV Medicine, 2010, 11, 216-224.	2.2	33
350	Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field. Clinical Trials, 2010, 7, 19-35.	1.6	33
351	Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development. Aids, 2001, 15, 2211-2220.	2.2	32
352	Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?. Aids, 2007, 21, 599-606.	2.2	32
353	Addressing social issues in a universal HIV test and treat intervention trial (ANRS 12249 TasP) in South Africa: methods for appraisal. BMC Public Health, 2015, 15, 209.	2.9	32
354	Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 126-133.	2.1	32
355	From Doxastic to Epistemic: A Typology and Critique of Qualitative Interview Styles. Qualitative Inquiry, 2020, 26, 291-305.	1.4	32
356	An audit of antiretroviral treatment use in HIV-infected patients in a London clinic: the limitations of observational databases when auditing antiretroviral treatment use. HIV Medicine, 2003, 4, 87-93.	2.2	31
357	Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study. HIV Medicine, 2011, 12, 583-593.	2.2	31
358	The potential role of long-acting injectable cabotegravir–rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis. The Lancet Global Health, 2021, 9, e620-e627.	6.3	31
359	The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. Aids, 2012, 26, 1691-1705.	2.2	31
360	Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antiviral Therapy, 2008, 13, 927-36.	1.0	31

#	Article	IF	CITATIONS
361	A Randomized Trial to Evaluate Continuation versus Discontinuation of Lamivudine in Individuals Failing A Lamivudine-Containing Regimen: The Colate Trial. Antiviral Therapy, 2006, 11, 761-770.	1.0	31
362	Markers of HIV-1 disease progression in individuals with haemophilia coinfected with hepatitis C virus: a longitudinal study. Lancet, The, 2002, 360, 1546-1551.	13.7	30
363	Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures. Aids, 2007, 21, 1423-1430.	2.2	30
364	The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. Aids, 2010, 24, 1917-1922.	2.2	30
365	The potential impact of RV144-like vaccines in rural South Africa: A study using the STDSIM microsimulation model. Vaccine, 2011, 29, 6100-6106.	3.8	30
366	Partners of people on ART - a New Evaluation of the Risks (The PARTNER study): design and methods. BMC Public Health, 2012, 12, 296.	2.9	30
367	Antiretroviral Therapy to Prevent HIV Acquisition in Serodiscordant Couples in a Hyperendemic Community in Rural South Africa. Clinical Infectious Diseases, 2016, 63, 548-554.	5.8	30
368	The Progression of HIV disease in a haemophilic cohort followed for 12 years. British Journal of Haematology, 1993, 83, 330-333.	2.5	29
369	Decline in Esophageal Candidiasis and Use of Antimycotics in European Patients with HIV. American Journal of Gastroenterology, 2005, 100, 1446-1454.	0.4	29
370	CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era. Aids, 2010, 24, 2697-2704.	2.2	29
371	Second-Line Antiretroviral Therapy in a Workplace and Community-Based Treatment Programme in South Africa: Determinants of Virological Outcome. PLoS ONE, 2012, 7, e36997.	2.5	29
372	Modelling HIV incidence and survival from age-specific seroprevalence after antiretroviral treatment scale-up in rural South Africa. Aids, 2013, 27, 2471-2479.	2.2	29
373	The effects of alcohol use on rebleeding and mortality in patients with alcoholic cirrhosis following variceal haemorrhage. Journal of Hepatology, 1992, 14, 99-103.	3.7	28
374	Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations <sup>*</sup> . HIV Medicine, 2010, 11, 432-438.	2.2	28
375	Association between exposure to antiretroviral drugs and the incidence of hypertension in <scp>HIV</scp> â€positive persons: the Data Collection on Adverse Events of Antiâ€ <scp>HIV</scp> Drugs (D:A:D) study. HIV Medicine, 2018, 19, 605-618.	2.2	28
376	How Can Programs Better Support Female Sex Workers to Avoid HIV Infection in Zimbabwe? A Prevention Cascade Analysis. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 24-35.	2.1	28
377	Evolution of Transmitted HIV-1 with Drug-Resistance Mutations in the Absence of Therapy: Effects on Cd4 <sup>+</sup> T-Cell Count and HIV-1 Rna Load. Antiviral Therapy, 2006, 11, 173-178.	1.0	28
378	Immune markers and viral load after HIV-1 seroconversion as predictors of disease progression in a cohort of haemophilic men. Aids, 1998, 12, 1347-1352.	2.2	27

#	Article	IF	CITATIONS
379	Evaluation of HIV Protease Inhibitor Use and the Risk of Sudden Death or Nonhemorrhagic Stroke. Journal of Infectious Diseases, 2012, 205, 535-539.	4.0	27
380	Screening for chronic comorbid diseases in people with <scp>HIV</scp> : the need for a strategic approach. HIV Medicine, 2013, 14, 1-11.	2.2	27
381	Costâ€effectiveness of routine viral load monitoring in low―and middleâ€income countries: a systematic review. Journal of the International AIDS Society, 2017, 20, e25006.	3.0	27
382	Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. Aids, 1997, 11, 169-175.	2.2	26
383	Risk of Cancer in Patients with HIV Disease. International Journal of STD and AIDS, 1999, 10, 38-42.	1.1	26
384	Use of Viral Load Measured After 4 Weeks of Highly Active Antiretroviral Therapy to Predict Virologic Outcome at 24 Weeks for HIV-1???Positive Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 37, 1155-1159.	2.1	26
385	Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. Aids, 2004, 18, 1795-1804.	2.2	26
386	Should HIV therapy be started at a CD4 cell count above 350 cells/μl in asymptomatic HIV-1-infected patients?. Current Opinion in Infectious Diseases, 2009, 22, 191-197.	3.1	26
387	Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir. Aids, 2017, 31, 485-492.	2.2	26
388	Effect of HIV self-testing on the number of sexual partners among female sex workers in Zambia. Aids, 2018, 32, 645-652.	2.2	26
389	Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study. Journal of the International AIDS Society, 2019, 22, e25297.	3.0	26
390	The ââ,¬ËœAntiretrovirals, Sexual Transmission Risk and Attitudesââ,¬â,,¢ (ASTRA) Study. Design, Methods and Participant Characteristics. PLoS ONE, 2013, 8, e77230.	d 2.5	26
391	p24 antigenaemia, CD4 lymphocyte counts and the development of AIDS. Aids, 1991, 5, 1217-1222.	2.2	25
392	Two decades of HIV infection in a cohort of haemophilic individuals: clinical outcomes and response to highly active antiretroviral therapy. Aids, 2000, 14, 1001-1007.	2.2	25
393	The Impact of Transmitted Drug-Resistance on Treatment Selection and Outcome of First-Line Highly Active Antiretroviral Therapy (HAART). Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 633-639.	2.1	25
394	Data linkage reduces loss to follow-up in an observational HIV cohort study. Journal of Clinical Epidemiology, 2010, 63, 1101-1109.	5.0	25
395	Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. Aids, 2014, 28, 1791-1796.	2.2	25
396	High percentage of undiagnosed HIV cases within a hyperendemic South African community: a population-based study. Journal of Epidemiology and Community Health, 2018, 72, 168-172.	3.7	25

#	Article	IF	CITATIONS
397	Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects. Journal of the International AIDS Society, 2019, 22, e25352.	3.0	25
398	Strengthening the scaleâ€up and uptake of effective interventions for sex workers for population impact in Zimbabwe. Journal of the International AIDS Society, 2019, 22, e25320.	3.0	25
399	The leukocyte count and risk of lung cancer. Cancer, 1992, 69, 680-684.	4.1	24
400	Antiviral therapy. Nature, 1995, 375, 195-195.	27.8	24
401	Participation in clinical studies among patients infected with HIV-1 in a single treatment centre over 12 years. HIV Medicine, 2000, 1, 212-218.	2.2	24
402	What is the risk of mortality following diagnosis of multidrug-resistant HIV-1?. Journal of Antimicrobial Chemotherapy, 2008, 61, 705-713.	3.0	24
403	The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy. HIV Medicine, 2009, 10, 35-43.	2.2	24
404	Modelling the Potential Population Impact and Cost-Effectiveness of Self-Testing for HIV: Evaluation of Data Requirements. AIDS and Behavior, 2014, 18, 450-458.	2.7	24
405	Human rights protections and HIV prevalence among MSM who sell sex: Cross-country comparisons from a systematic review and meta-analysis. Global Public Health, 2018, 13, 414-425.	2.0	24
406	The EuroSIDA study: 25 years of scientific achievements. HIV Medicine, 2020, 21, 71-83.	2.2	24
407	Cost-Effectiveness of HIV Drug Resistance Testing to Inform Switching to Second Line Antiretroviral Therapy in Low Income Settings. PLoS ONE, 2014, 9, e109148.	2.5	24
408	Changes in Viral Load in People with Virological Failure who Remain on the Same Haart Regimen. Antiviral Therapy, 2003, 8, 127-136.	1.0	24
409	Effect of Transient Antiretroviral Treatment during acute HIV Infection: Comparison of the Quest Trial Results with CASCADE Natural History Study. Antiviral Therapy, 2007, 12, 189-194.	1.0	24
410	Long-term Perspective on the Prevalent-Cohort Biases in Studies of Human Immunodeficiency Virus Progression. American Journal of Epidemiology, 1997, 146, 543-551.	3.4	23
411	Cytomegalovirus Seropositivity and Human Immunodeficiency Virus Type 1 RNA Levels in Individuals with Hemophilia. Journal of Infectious Diseases, 2000, 181, 1800-1803.	4.0	23
412	The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI <sup>*</sup> . HIV Medicine, 2012, 13, 62-72.	2.2	23
413	Human resources needs for universal access to antiretroviral therapy in South Africa: a time and motion study. Human Resources for Health, 2012, 10, 39.	3.1	23
414	Update on HIV in Western Europe. Current HIV/AIDS Reports, 2014, 11, 177-185.	3.1	23

#	Article	IF	CITATIONS
415	Statistical design and analysis plan for an impact evaluation of an HIV treatment and prevention intervention for female sex workers in Zimbabwe: a study protocol for a cluster randomised controlled trial. Trials, 2016, 17, 6.	1.6	23
416	Engagement in HIV Care Among Young Female Sex Workers in Zimbabwe. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 358-366.	2.1	23
417	Preferences for HIV testing services among men who have sex with men in the UK: A discrete choice experiment. PLoS Medicine, 2019, 16, e1002779.	8.4	23
418	British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Medicine, 2003, 4 Suppl 1, 1-41.	2.2	23
419	Regional survival differences across Europe In HIV-positive people: the EuroSIDA study. Aids, 1999, 13, 2281-2288.	2.2	22
420	Plasma Viral Load Concentrations in Women and Men From Different Exposure Categories and With Known Duration of HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 25, 56-62.	2.1	22
421	The changing demographics of new HIV diagnoses at a London centre from 1994 to 2000. HIV Medicine, 2002, 3, 129-134.	2.2	22
422	A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men. International Journal of Epidemiology, 2007, 36, 1309-1318.	1.9	22
423	Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK. HIV Medicine, 2008, 9, 47-56.	2.2	22
424	Effects of age on symptom burden, mental health and quality of life amongst people with HIV in the UK. Journal of the International AIDS Society, 2014, 17, 19511.	3.0	22
425	O1â€Is pre-exposure prophylaxis for hiv prevention cost-effective in men who have sex with men who engage in condomless sex in the uk?. Sexually Transmitted Infections, 2015, 91, A1.1-A1.	1.9	22
426	When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 214-221.	2.1	22
427	Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. International Journal of Epidemiology, 2017, 46, dyw211.	1.9	22
428	Point-of-Care Viral Load Testing for Sub-Saharan Africa: Informing a Target Product Profile. Open Forum Infectious Diseases, 2016, 3, ofw161.	0.9	22
429	Accuracy of selfâ€report of <scp>HIV</scp> viral load among people with <scp>HIV</scp> on antiretroviral treatment. HIV Medicine, 2017, 18, 463-473.	2.2	22
430	Potential Impact and Cost-Effectiveness of Condomless-Sex–Concentrated PrEP in KwaZulu-Natal Accounting for Drug Resistance. Journal of Infectious Diseases, 2021, 223, 1345-1355.	4.0	22
431	Are Specific Antiretrovirals associated with an Increased Risk of Discontinuation due to Toxicities or Patient/Physician Choice in patients with Hepatitis C Virus Coinfection?. Antiviral Therapy, 2005, 10, 779-790.	1.0	22
432	Prognostic scores for detecting a high risk group: Estimating the sensitivity when applied to new data. Statistics in Medicine, 1990, 9, 1189-1198.	1.6	21

#	Article	IF	CITATIONS
433	Drug switching and virologic-based endpoints in trials of antiretroviral drugs for HIV infection. Aids, 2004, 18, 365-370.	2.2	21
434	Factors associated with viral rebound among highly treatmentâ€experienced HIVâ€positive patients who have achieved viral suppression. HIV Medicine, 2009, 10, 19-27.	2.2	21
435	Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?. Aids, 2015, 29, 2323-2333.	2.2	21
436	HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK. Journal of Antimicrobial Chemotherapy, 2016, 71, 3487-3494.	3.0	21
437	The per-protocol effect of immediate versus deferred antiretroviral therapy initiation. Aids, 2016, 30, 2659-2663.	2.2	21
438	Clinically significant depressive symptoms and sexual behaviour among men who have sex with men. BJPsych Open, 2017, 3, 127-137.	0.7	21
439	Failure to initiate HIV treatment in patients with high CD 4 counts: evidence from demographic surveillance in rural SouthÂAfrica. Tropical Medicine and International Health, 2018, 23, 206-220.	2.3	21
440	In vivo HIV-1 replicative capacity in early and advanced infection. Aids, 1999, 13, 67-73.	2.2	21
441	Access to medical care one year prior to diagnosis in 100 HIV-positive women. Family Practice, 1997, 14, 255-257.	1.9	20
442	Study Protocol for the Evaluation of the Potential for Durable Viral Suppression After Quadruple HAART With or Without HIV Vaccination: The QUEST Study. HIV Clinical Trials, 2001, 2, 438-444.	2.0	20
443	Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters. HIV Medicine, 2011, 12, 289-298.	2.2	20
444	Potential Future Impact of a Partially Effective HIV Vaccine in a Southern African Setting. PLoS ONE, 2014, 9, e107214.	2.5	20
445	Finger Prick Dried Blood Spots for HIV Viral Load Measurement in Field Conditions in Zimbabwe. PLoS ONE, 2015, 10, e0126878.	2.5	20
446	Baseline cardiovascular risk in the <scp>INSIGHT</scp> Strategic Timing of AntiRetroviral Treatment ( <scp>START</scp> ) trial. HIV Medicine, 2015, 16, 46-54.	2.2	20
447	Cost Effectiveness of Potential ART Adherence Monitoring Interventions in Sub-Saharan Africa. PLoS ONE, 2016, 11, e0167654.	2.5	20
448	Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. Open Forum Infectious Diseases, 2016, 3, ofw009.	0.9	20
449	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. Clinical Infectious Diseases, 2016, 63, ciw519.	5.8	20
450	Longitudinal Analysis of the Associations between Antiretroviral Therapy, Viraemia and Immunosuppression with Lipid Levels: The D:A:D Study. Antiviral Therapy, 2016, 21, 495-506.	1.0	20

#	Article	IF	CITATIONS
451	Pilot phase of an internet-based RCT of HIVST targeting MSM and transgender people in England and Wales: advertising strategies and acceptability of the intervention. BMC Infectious Diseases, 2019, 19, 699.	2.9	20
452	Costâ€perâ€diagnosis as a metric for monitoring costâ€effectiveness of HIV testing programmes in lowâ€income settings in southern Africa: health economic and modelling analysis. Journal of the International AIDS Society, 2019, 22, e25325.	3.0	20
453	HIV risk and pre-exposure prophylaxis interest among female bar workers in Dar es Salaam: cross-sectional survey. BMJ Open, 2019, 9, e023272.	1.9	20
454	Use of HIV pre-exposure prophylaxis among men who have sex with men in England: data from the AURAH2 prospective study. Lancet Public Health, The, 2020, 5, e501-e511.	10.0	20
455	Human Resources for Treating HIV/AIDS: Are the Preventive Effects of Antiretroviral Treatment a Game Changer?. PLoS ONE, 2016, 11, e0163960.	2.5	20
456	Effect of eliminating CD4-count thresholds on HIV treatment initiation in South Africa: An empirical modeling study. PLoS ONE, 2017, 12, e0178249.	2.5	20
457	The risks and benefits of providing HIV services during the COVID-19 pandemic. PLoS ONE, 2021, 16, e0260820.	2.5	20
458	Changes over time in post-seroconversion CD4 cell counts in the Italian HIV-Seroconversion Study: 1985-2002. Aids, 2005, 19, 331-5.	2.2	20
459	Refocusing health promotion for syphilis prevention: results of a case-control study of men who have sex with men on England's south coast. Sexually Transmitted Infections, 2006, 82, 80-83.	1.9	19
460	Comparative Effectiveness of Initial Antiretroviral Therapy Regimens. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 253-260.	2.1	19
461	Sensitive Assessment of the Virologic Outcomes of Stopping and Restarting Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy. PLoS ONE, 2013, 8, e69266.	2.5	19
462	Capturing the spatial variability of HIV epidemics in South Africa and Tanzania using routine healthcare facility data. International Journal of Health Geographics, 2018, 17, 27.	2.5	19
463	CD4 cell count changes in individuals with counts above 500 cells/mm3 and viral loads below 50 copies/ml on antiretroviral therapy. Aids, 2002, 16, 1073-1075.	2.2	19
464	Response to Efavirenz-Containing Regimens in Previously Antiretroviral-Naive HIV-Positive Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 62-67.	2.1	19
465	"It went through the roof†an observation study exploring the rise in PrEP uptake among Zimbabwean female sex workers in response to adaptations during Covidâ€19. Journal of the International AIDS Society, 2021, 24, e25813.	3.0	19
466	Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study. Lancet HIV,the, 2022, 9, e353-e362.	4.7	19
467	Beta-2 microglobulin as a predictor of prognosis in HIV-infected men with haemophilia: a proposed strategy for use in clinical care. British Journal of Haematology, 1994, 86, 366-371.	2.5	18
468	Does short-term virologic failure translate to clinical events in antiretroviral-naÃ <sup>-</sup> ve patients initiating antiretroviral therapy in clinical practice?. Aids, 2008, 22, 2481-2492.	2.2	18

#	Article	IF	CITATIONS
469	Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?. Aids, 2008, 22, 349-356.	2.2	18
470	HIV Treatment-as-Prevention Research at a Crossroads. PLoS Medicine, 2014, 11, e1001654.	8.4	18
471	Innovations in health and demographic surveillance systems to establish the causal impacts of HIV policies. Current Opinion in HIV and AIDS, 2015, 10, 483-494.	3.8	18
472	Association of Suboptimal Antiretroviral Therapy Adherence With Inflammation in Virologically Suppressed Individuals Enrolled in the SMART Study. Open Forum Infectious Diseases, 2018, 5, ofx275.	0.9	18
473	Large age shifts in HIV-1 incidence patterns in KwaZulu-Natal, South Africa. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	18
474	Updated European recommendations for the clinical use of HIV drug resistance testing. Antiviral Therapy, 2004, 9, 829-48.	1.0	18
475	Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. Aids, 1997, 11, 461-467.	2.2	17
476	Ongoing changes in HIV RNA levels during untreated HIV infection: implications for CD4 cell count depletion. Aids, 2010, 24, 1561-1567.	2.2	17
477	A simple selfâ€reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy. HIV Medicine, 2016, 17, 124-132.	2.2	17
478	Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study. PLoS Medicine, 2017, 14, e1002424.	8.4	17
479	Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) Study. Journal of Infectious Diseases, 2018, 217, 405-412.	4.0	17
480	Modelled <i>in vivo</i> HIV Fitness under drug Selective Pressure and Estimated Genetic Barrier Towards Resistance are Predictive for Virological Response. Antiviral Therapy, 2008, 13, 399-408.	1.0	17
481	Survival in 2367 Zidovudine-Treated Patients According to Use of Other Nucleoside Analogue Drugs. Journal of Acquired Immune Deficiency Syndromes, 1998, 17, 239-244.	0.3	16
482	Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study. Aids, 2008, 22, 1943-1950.	2.2	16
483	Biomarkers to Monitor Safety in People on ART and Risk of Mortality. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 51-58.	2.1	16
484	Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals. Aids, 2017, 31, 1261-1270.	2.2	16
485	Reflecting the real value of health care resources in modelling and cost-effectiveness studies—The example of viral load informed differentiated care. PLoS ONE, 2018, 13, e0190283.	2.5	16
486	Effect of Changes in Body Mass Index on the Risk of Cardiovascular Disease and Diabetes Mellitus in HIV-Positive Individuals: Results From the D:A:D Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, 579-586.	2.1	16

#	Article	IF	CITATIONS
487	A Practical Guide to Applying the Intention-to-Treat Principle to Clinical Trials in HIV Infection. HIV Clinical Trials, 2000, 1, 31-38.	2.0	15
488	Will the drugs still work? Transmission of resistant HIV. Nature Medicine, 2001, 7, 993-994.	30.7	15
489	Two-Year Outcome of a Multidrug Regimen in Patients Who Did Not Respond to a Protease Inhibitor Regimen. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 58-61.	2.1	15
490	Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C. Scandinavian Journal of Infectious Diseases, 2006, 38, 1092-1097.	1.5	15
491	The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors. Aids, 2007, 21, 2033-2042.	2.2	15
492	Abacavir use and risk of recurrent myocardial infarction. Aids, 2018, 32, 79-88.	2.2	15
493	The impact of ART initiation on household food security over time. Social Science and Medicine, 2018, 198, 175-184.	3.8	15
494	Protocol, rationale and design of SELPHI: a randomised controlled trial assessing whether offering free HIV self-testing kits via the internet increases the rate of HIV diagnosis. BMC Infectious Diseases, 2018, 18, 531.	2.9	15
495	Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study. EClinicalMedicine, 2019, 13, 91-100.	7.1	15
496	Associations of depression and anxiety symptoms with sexual behaviour in women and heterosexual men attending sexual health clinics: a cross-sectional study. Sexually Transmitted Infections, 2019, 95, 254-261.	1.9	15
497	HIV selfâ€testing intervention experiences and kit usability: results from a qualitative study among men who have sex with men in theÂSELPHIÂ(Selfâ€Testing Public Health Intervention) randomized controlled trial in England and Wales. HIV Medicine, 2020, 21, 189-197.	2.2	15
498	Impact and acceptability of HIV self-testing for trans men and trans women: A mixed-methods subgroup analysis of the SELPHI randomised controlled trial and process evaluation in England and Wales. EClinicalMedicine, 2021, 32, 100700.	7.1	15
499	Does European or non-European origin influence health care and prognosis for HIV patients in Europe?. HIV Medicine, 1999, 1, 2-9.	2.2	14
500	Changes in Lipids and Lipoprotein Particle Concentrations After Interruption of Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 275-284.	2.1	14
501	Second line protease inhibitor (PI/r) based antiretroviral therapy (ART) after non-nucleoside reverse transcriptase inhibitor (NNRTI) failure: impact of nucleoside (NRTI) backbone. Antiviral Therapy, 2012, 18, 213-219.	1.0	14
502	Cost-Effectiveness of Tenofovir Instead of Zidovudine for Use in First-Line Antiretroviral Therapy in Settings without Virological Monitoring. PLoS ONE, 2012, 7, e42834.	2.5	14
503	Sociobehavioral and community predictors of unsuppressed HIV viral load. Aids, 2019, 33, 559-569.	2.2	14
504	Recreational drug use and use of drugs associated with chemsex among HIV-negative and HIV-positive heterosexual men and women attending sexual health and HIV clinics in England. International Journal of Drug Policy, 2021, 91, 103101.	3.3	14

#	Article	IF	CITATIONS
505	Analysis of Virological Efficacy in Trials of Antiretroviral Regimens: Drawbacks of Not Including Viral Load Measurements after Premature Discontinuation of Therapy. Antiviral Therapy, 2002, 7, 271-281.	1.0	14
506	HIV-1 dynamics after transient antiretroviral therapy: Implications for pathogenesis and clinical management. Journal of Medical Virology, 1997, 53, 261-265.	5.0	13
507	RE: "CIGARETTE SMOKING AND SUICIDE: A PROSPECTIVE STUDY OF 300,000 MALE ACTIVE-DUTY ARMY SOLDIERS― American Journal of Epidemiology, 2001, 153, 307-308.	3.4	13
508	Abacavir and increased risk of myocardial infarction – Authors' reply. Lancet, The, 2008, 372, 804-805.	13.7	13
509	Predicting antiretroviral drug resistance from the latest or the cumulative genotype. Antiviral Therapy, 2011, 16, 373-381.	1.0	13
510	Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2011, 66, 901-911.	3.0	13
511	Association Between ALT Level and the Rate of Cardio/Cerebrovascular Events in HIV-Positive Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 456-463.	2.1	13
512	Socio-economic factors and virological suppression among people diagnosed with HIV in the United Kingdom: results from the ASTRA study. Journal of the International AIDS Society, 2014, 17, 19533.	3.0	13
513	Sexual behaviour, recreational drug use and hepatitis C co-infection in HIV-diagnosed men who have sex with men in the United Kingdom: results from the ASTRA study. Journal of the International AIDS Society, 2014, 17, 19630.	3.0	13
514	Transmission risk behaviour at enrolment in participants in the <scp>INSIGHT S</scp> trategic <scp>T</scp> iming of <scp>A</scp> nti <scp>R</scp> etroviral <scp>T</scp> reatment ( <scp>START</scp> ) trial. HIV Medicine, 2015, 16, 64-76.	2.2	13
515	Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa. Journal of Infectious Diseases, 2016, 214, 73-79.	4.0	13
516	Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance. Aids, 2018, 32, 327-335.	2.2	13
517	Chronic Kidney Disease Risk in African and Caribbean Populations With HIV. Journal of Infectious Diseases, 2018, 218, 1767-1772.	4.0	13
518	Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa. Vaccine, 2019, 37, 2258-2267.	3.8	13
519	Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIVâ€positive individuals. Statistics in Medicine, 2019, 38, 2428-2446.	1.6	13
520	Understanding early uptake of PrEP by female sex workers in Zimbabwe. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2021, 33, 729-735.	1.2	13
521	Trends in HIV incidence between 2013–2019 and association of baseline factors with subsequent incident HIV among gay, bisexual, and other men who have sex with men attending sexual health clinics in England: A prospective cohort study. PLoS Medicine, 2021, 18, e1003677.	8.4	13
522	Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 294-299.	2.1	13

#	Article	IF	CITATIONS
523	Attitudes of People in the UK with HIV Who Are Antiretroviral (ART) NaÃ⁻ve to Starting ART at High CD4 Counts for Potential Health Benefit or to Prevent HIV Transmission. PLoS ONE, 2014, 9, e97340.	2.5	13
524	Clinical Progression Rates by CD4 Cell Category Before and After the Initiation of Combination Antiretroviral Therapy (cART). Open AIDS Journal, 2008, 2, 3-9.	0.5	13
525	Factors associated with the CD4+ lymphocyte count at diagnosis of acquired immunodeficiency syndrome. Journal of Clinical Epidemiology, 1996, 49, 1253-1258.	5.0	12
526	Response to Highly Active Antiretroviral Therapy According to Duration of HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 473-479.	2.1	12
527	Reconstitution of Herpes Simplex Virus–Specific T Cell Immunity in HIVâ€Infected Patients Receiving Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2007, 195, 410-415.	4.0	12
528	Impact of HIVâ€1 Reverse Transcriptase Polymorphism F214L on Virological Response to Thymidine Analogue–Based Regimens in Antiretroviral Therapy (ART)–Naive and ARTâ€Experienced Patients. Journal of Infectious Diseases, 2007, 196, 1180-1190.	4.0	12
529	Estimated average annual rate of change of CD4+ T-cell counts in patients on combination antiretroviral therapy. Antiviral Therapy, 2010, 15, 563-570.	1.0	12
530	Haemoglobin and Anaemia in the Smart Study. Antiviral Therapy, 2011, 16, 329-337.	1.0	12
531	CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. Aids, 2013, 27, 907-918.	2.2	12
532	HIV resistance testing and detected drug resistance in Europe. Aids, 2015, 29, 1379-1389.	2.2	12
533	Using interviewer random effects to remove selection bias from HIV prevalence estimates. BMC Medical Research Methodology, 2015, 15, 8.	3.1	12
534	Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 311-318.	2.1	12
535	Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma. Journal of the National Cancer Institute, 2018, 110, 598-607.	6.3	12
536	Longitudinal Trends in the Prevalence of Detectable HIV Viremia: Population-Based Evidence From Rural KwaZulu-Natal, South Africa. Clinical Infectious Diseases, 2018, 66, 1254-1260.	5.8	12
537	Factors Associated With Persistence of Plasma HIV-1 RNA During Long-term Continuously Suppressive Firstline Antiretroviral Therapy. Open Forum Infectious Diseases, 2018, 5, ofy032.	0.9	12
538	Viral breakthrough after suppression with highly active antiretroviral therapy. Aids, 2003, 17, 768-770.	2.2	12
539	A Cross-Sectional Study on Attitudes to and Understanding of Risk of Acquisition of HIV: Design, Methods and Participant Characteristics. JMIR Research Protocols, 2016, 5, e58.	1.0	12
540	The Relationship between Cd4 Cell Count Nadirs and the Toxicity Profiles of Antiretroviral Regimens. Antiviral Therapy, 2005, 10, 459-467.	1.0	12

#	Article	IF	CITATIONS
541	A practical approach to adjusting for attrition bias in HIV clinical trials with serial marker responses. Aids, 1998, 12, 1155-1161.	2.2	11
542	The Quest Trial, a paradigm of HIV collaborative research. Nature Medicine, 2000, 6, 1194-1194.	30.7	11
543	Initiatives for Developing and Comparing Genotype Interpretation Systems: External Validation of Existing Systems for Didanosine against Virological Response. Journal of Infectious Diseases, 2008, 198, 470-480.	4.0	11
544	Evaluating the extent of potential resistance to preâ€exposure prophylaxis within the <scp>UK HIV</scp> â€1â€infectious population of men who have sex with men. HIV Medicine, 2012, 13, 309-314.	2.2	11
545	Insurability of HIV-positive people treated with antiretroviral therapy in Europe. Aids, 2013, 27, 1641-1655.	2.2	11
546	Population level usage of health services, and HIV testing and care, prior to decentralization of antiretroviral therapy in Agago District in rural Northern Uganda. BMC Health Services Research, 2015, 15, 527.	2.2	11
547	Ethnicity and sexual risk in heterosexual people attending sexual health clinics in England: a cross-sectional, self-administered questionnaire study. Sexually Transmitted Infections, 2018, 94, 384-391.	1.9	11
548	Brief Report: Intimate Partner Violence and Antiretroviral Therapy Initiation Among Female Sex Workers Newly Diagnosed With HIV in Zambia: A Prospective Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 435-439.	2.1	11
549	Do HIV treatment eligibility expansions crowd out the sickest? Evidence from rural South Africa. Tropical Medicine and International Health, 2018, 23, 968-979.	2.3	11
550	First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines. Aids, 2020, 34, 1823-1831.	2.2	11
551	Provision of HIV viral load testing services in Zimbabwe: Secondary data analyses using data from health facilities using the electronic Patient Monitoring System. PLoS ONE, 2021, 16, e0245720.	2.5	11
552	A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial. Antiviral Therapy, 2006, 11, 761-70.	1.0	11
553	Population Trends in the Prevalence and Patterns of Protease Resistance Related to Exposure to Unboosted and Boosted Protease Inhibitors. Antiviral Therapy, 2008, 13, 771-777.	1.0	11
554	Response to Highly Active Antiretroviral Therapy According to Duration of HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 473-479.	2.1	10
555	Overcoming obstacles to late presentation for HIV infection in Europe. HIV Medicine, 2011, 12, 246-249.	2.2	10
556	Determinants of IL-6 levels during HIV infection. Journal of the International AIDS Society, 2014, 17, 19482.	3.0	10
557	Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals. Aids, 2016, 30, 1583-1596.	2.2	10
558	Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. Lancet HIV,the, 2017, 4, e251-e259.	4.7	10

#	Article	IF	CITATIONS
559	Opportunities and Challenges in HIV Treatment as Prevention Research: Results from the ANRS 12249 Cluster-Randomized Trial and Associated Population Cohort. Current HIV/AIDS Reports, 2020, 17, 97-108.	3.1	10
560	CD4 lymphocyte depletion prior to the development of AIDS. Aids, 1992, 6, 735-736.	2.2	9
561	Viral burden in HIV infection. Nature, 1994, 367, 124-124.	27.8	9
562	Changing treatment patterns among patients with HIV: Royal Free Hospital 1987-97. HIV Medicine, 1999, 1, 32-39.	2.2	9
563	Two-Year Outcome of a Multidrug Regimen in Patients Who Did Not Respond to a Protease Inhibitor Regimen. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 29, 58-61.	2.1	9
564	Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression. Aids, 2014, 28, 919-924.	2.2	9
565	Use of Surveillance Data on HIV Diagnoses with HIV-Related Symptoms to Estimate the Number of People Living with Undiagnosed HIV in Need of Antiretroviral Therapy. PLoS ONE, 2015, 10, e0121992.	2.5	9
566	Serum β2-Microglobulin at HIV-1 Seroconversion As a Predictor of Severe Immunodeficiency During 10 Years of Followup. Journal of Acquired Immune Deficiency Syndromes, 1996, 13, 262-266.	0.3	9
567	Comparison of immunodeficiency and AIDS defining conditions in HIV negative and HIV postive men with haemophilia A. BMJ: British Medical Journal, 1996, 312, 207-210.	2.3	9
568	Symptomatic Illness and Low CD4 Cell Count at HIV Seroconversion as Markers of Severe Primary HIV Infection. PLoS ONE, 2013, 8, e78642.	2.5	9
569	Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir. Aids, 2001, 15, 999-1008.	2.2	8
570	Definition of loss of virological response in trials of antiretroviral drugs. Aids, 2003, 17, 1997-1998.	2.2	8
571	Virological Response to Initial Antiretroviral Regimens Containing Abacavir or Tenofovir. Journal of Infectious Diseases, 2009, 200, 710-714.	4.0	8
572	Relative risk of death in the SMART study. Lancet Infectious Diseases, The, 2009, 9, 724-725.	9.1	8
573	DART points the way for HIV treatment programmes. Lancet, The, 2010, 375, 96-98.	13.7	8
574	Modelling the impact of treatment with individual antiretrovirals. Current Opinion in HIV and AIDS, 2011, 6, 124-130.	3.8	8
575	The impact of HIV drug resistance testing on changes to treatment. Aids, 2011, 25, 603-610.	2.2	8
576	Further research needed to support a policy of antiretroviral therapy as an HIV prevention initiative. Antiviral Therapy, 2013, 18, 285-7.	1.0	8

#	Article	IF	CITATIONS
577	Role of HIV Infection Duration and CD4 Cell Level at Initiation of Combination Anti-Retroviral Therapy on Risk of Failure. PLoS ONE, 2013, 8, e75608.	2.5	8
578	Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?. Aids, 2016, 30, 1629-1637.	2.2	8
579	Impact of decentralisation of antiretroviral therapy services on HIV testing and care at a population level in Agago District in rural Northern Uganda: results from the Lablite population surveys. International Health, 2017, 9, 91-99.	2.0	8
580	90-90-90 by 2020? Estimation and projection of the adult HIV epidemic and ART programme in Zimbabwe - 2017 to 2020. Journal of the International AIDS Society, 2018, 21, e25205.	3.0	8
581	Medication Side Effects and Retention in HIV Treatment: A Regression Discontinuity Study of Tenofovir Implementation in South Africa and Zambia. American Journal of Epidemiology, 2018, 187, 1990-2001.	3.4	8
582	Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. Journal of Infectious Diseases, 2019, 220, 1629-1634.	4.0	8
583	Enhancing national prevention and treatment services for sex workers in Zimbabwe: a process evaluation of the SAPPH-IRe trial. Health Policy and Planning, 2019, 34, 337-345.	2.7	8
584	Exploring Mechanisms of Action: Using a Testing Typology to Understand Intervention Performance in an HIV Self-Testing RCT in England and Wales. International Journal of Environmental Research and Public Health, 2020, 17, 466.	2.6	8
585	Patterns of multimorbidity and their association with hospitalisation: a population-based study of older adults in urban Tanzania. Age and Ageing, 2021, 50, 1349-1360.	1.6	8
586	No need for secondary <i>Pneumocystis jirovecii</i> pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100Âcells/µL. Journal of the International AIDS Society, 2021, 24, e25726.	3.0	8
587	Potential impact of intervention strategies on COVID-19 transmission in Malawi: a mathematical modelling study. BMJ Open, 2021, 11, e045196.	1.9	8
588	Trial and error. Aids, 2003, 17, 619-623.	2.2	7
589	Predictors of CD4+ T-Cell Counts of HIV Type 1–Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. Journal of Infectious Diseases, 2013, 207, 759-767.	4.0	7
590	Prevalence of recreational drug use is indiscriminate across antiretroviral regimens of differing drug–drug interactions among MSM. Aids, 2016, 30, 810-812.	2.2	7
591	Virological failure and development of new resistance mutations according to <scp>CD</scp> 4 count at combination antiretroviral therapy initiation. HIV Medicine, 2016, 17, 368-372.	2.2	7
592	Populationâ€level decline in BMI and systolic blood pressure following mass HIV treatment: Evidence from rural KwaZuluâ€Natal. Obesity, 2017, 25, 200-206.	3.0	7
593	Prevention of HIV transmission by antiretroviral therapy. Lancet HIV,the, 2018, 5, e108-e109.	4.7	7
594	Long term effect of primary health care training on HIV testing: A quasi-experimental evaluation of the Sexual Health in Practice (SHIP) intervention. PLoS ONE, 2018, 13, e0199891.	2.5	7

#	Article	IF	CITATIONS
595	Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance. Journal of Antimicrobial Chemotherapy, 2019, 74, 746-753.	3.0	7
596	Temporal trends of population viral suppression in the context of Universal Test and Treat: the ANRS 12249 TasP trial in rural South Africa. Journal of the International AIDS Society, 2019, 22, e25402.	3.0	7
597	Serious clinical events in HIV-positive persons with chronic kidney disease. Aids, 2019, 33, 2173-2188.	2.2	7
598	Sexual risk and HIV testing disconnect in men who have sex with men (MSM) recruited to an online HIV selfâ€ŧesting trial. HIV Medicine, 2020, 21, 588-598.	2.2	7
599	All-cause hospitalization according to demographic group in people living with HIV in the current antiretroviral therapy era. Aids, 2021, 35, 245-255.	2.2	7
600	Impact of the coronavirus disease 2019-related global recession on the financing of the global HIV response. Aids, 2021, 35, 1143-1146.	2.2	7
601	Prospective association of social circumstance, socioeconomic, lifestyle and mental health factors with subsequent hospitalisation over 6–7 year follow up in people living with HIV. EClinicalMedicine, 2021, 31, 100665.	7.1	7
602	Attitudes to and Understanding of Risk of Acquisition of HIV Over Time: Design and Methods for an Internet-based Prospective Cohort Study Among UK Men Who Have Sex With Men (the AURAH2 Study). JMIR Research Protocols, 2016, 5, e128.	1.0	7
603	HIV Survival Benefit Associated with Earlier Antiviral Therapy. Annals of Internal Medicine, 2004, 140, 578.	3.9	7
604	Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response. Antiviral Therapy, 2008, 13, 399-407.	1.0	7
605	Albumin, haemostasis and cardiovascular disease. Fibrinolysis, 1991, 5, 131.	0.5	6
606	Studies of prognostic markers in HIV infection. Aids, 1992, 6, 1391-1394.	2.2	6
607	Comparison of Single and Boosted Protease Inhibitor Versus Nonnucleoside Reverse Transcriptase Inhibitor–Containing cART Regimens in Antiretroviral-NaÃ⁻ve Patients Starting cART After January 1, 2000. HIV Clinical Trials, 2006, 7, 271-284.	2.0	6
608	A Comparison between Abacavir and Efavirenz as the Third Drug Used in Combination with a Background Therapy Regimen of 2 Nucleoside Reverseâ€Transcriptase Inhibitors in Patients with Initially Suppressed Viral Loads. Journal of Infectious Diseases, 2006, 194, 20-28.	4.0	6
609	TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals. Aids, 2008, 22, 737-740.	2.2	6
610	How does HIV impact on non-AIDS events in the era of HAART?. International Journal of STD and AIDS, 2009, 20, 1-3.	1.1	6
611	Uncertainty as to Whether the Use of Antiretroviral Therapy for Persons Recently Infected with HIV Has a Favorable Riskâ€ŧoâ€Benefit Ratio. Clinical Infectious Diseases, 2009, 48, 1162-1162.	5.8	6
612	A method to estimate the size and characteristics of HIV-positive populations using an individual-based stochastic simulation model. Epidemiology, 2015, 27, 1.	2.7	6

#	Article	IF	CITATIONS
613	Preâ€therapy inflammation and coagulation activation and longâ€term <scp>CD4</scp> count responses to the initiation of antiretroviral therapy. HIV Medicine, 2015, 16, 449-454.	2.2	6
614	Boosted Lopinavir– Versus Boosted Atazanavir–Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. Clinical Infectious Diseases, 2015, 60, 1262-1268.	5.8	6
615	A method for statistical analysis of repeated residential movements to link human mobility and HIV acquisition. PLoS ONE, 2019, 14, e0217284.	2.5	6
616	Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV. Journal of Virus Eradication, 2019, 5, 204-	21· <del>1</del> .	6
617	Prevalence and correlates of depressive symptoms among gay, bisexual and other men who have sex with men in the PROUD randomised clinical trial of HIV pre-exposure prophylaxis. BMJ Open, 2019, 9, e031085.	1.9	6
618	Effectiveness of Transmitted Drug Resistance Testing Before Initiation of Antiretroviral Therapy in HIV-Positive Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 314-320.	2.1	6
619	Early HIV treatment and labour outcomes: A case study of mining workers in South Africa. Health Economics (United Kingdom), 2019, 28, 204-218.	1.7	6
620	Impact of immediate initiation of antiretroviral therapy on HIV patient satisfaction. Aids, 2020, 34, 267-276.	2.2	6
621	HIV incidence declines in a rural South African population: a G-imputation approach for inference. BMC Public Health, 2020, 20, 1205.	2.9	6
622	Developing and Validating Metamodels of a Microsimulation Model of Infant HIV Testing and Screening Strategies Used in a Decision Support Tool for Health Policy Makers. MDM Policy and Practice, 2020, 5, 238146832093289.	0.9	6
623	HIV seroconcordance among heterosexual couples in rural KwaZuluâ€Natal, South Africa: a populationâ€based analysis. Journal of the International AIDS Society, 2020, 23, e25432.	3.0	6
624	The Impact of Immunosuppression on Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: The D:A:D Study. Journal of Infectious Diseases, 2021, 223, 632-637.	4.0	6
625	Causes of hospitalisation among a cohort of people with HIV from a London centre followed from 2011 to 2018. BMC Infectious Diseases, 2021, 21, 395.	2.9	6
626	A stepped-wedge randomised trial on the impact of early ART initiation on HIV-patients' economic outcomes in Eswatini. ELife, 2020, 9, .	6.0	6
627	TEN-YEAR FOLLOW-UP OF HIV INFECTION IN A HAEMOPHILIC COHORT. British Journal of Haematology, 1990, 75, 623-623.	2.5	5
628	Commentary: Balancing quantity and quality when designing epidemiological studies. International Journal of Epidemiology, 2003, 32, 58-59.	1.9	5
629	Theoretical rationale for the use of sequential single-drug antiretroviral therapy for treatment of HIV infection. Aids, 2003, 17, 1009-1016.	2.2	5
630	Twenty five years of HIV infection in haemophilic men in Britain: an observational study. BMJ: British Medical Journal, 2005, 331, 997-998.	2.3	5

#	Article	IF	CITATIONS
631	An audit of viral load in one clinical population to describe features of viraemic patients on antiretroviral therapy. HIV Medicine, 2008, 9, 208-213.	2.2	5
632	Predicting the potential benefits of early initiation of ART: time to do a trial to find out. Current Opinion in HIV and AIDS, 2009, 4, 165-166.	3.8	5
633	Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets. Aids, 2010, 24, 365-371.	2.2	5
634	Does Discordancy Between the CD4 Count and CD4 Percentage in HIV-Positive Individuals Influence Outcomes on Highly Active Antiretroviral Therapy?. Journal of Infectious Diseases, 2012, 205, 540-547.	4.0	5
635	Determining the Origins of Human Immunodeficiency Virus Type 1 Drug-resistant Minority Variants in People Who Are Recently Infected Using Phylogenetic Reconstruction. Clinical Infectious Diseases, 2018, 69, 1136-1143.	5.8	5
636	Getting to 90–90–90: Experiences from the MaxART Early Access to ART for All (EAAA) Trial in Eswatini. Current HIV/AIDS Reports, 2020, 17, 324-332.	3.1	5
637	Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a costâ€effectiveness analysis. Journal of the International AIDS Society, 2020, 23, e25494.	3.0	5
638	Optimizing infant HIV diagnosis with additional screening at immunization clinics in three subâ€Saharan African settings: a costâ€effectiveness analysis. Journal of the International AIDS Society, 2021, 24, e25651.	3.0	5
639	Costâ€effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States. Journal of the International AIDS Society, 2021, 24, e25690.	3.0	5
640	Opposing associations of depression with sexual behaviour: implications for epidemiological investigation among gay, bisexual and other men who have sex with men. Sexually Transmitted Infections, 2021, 97, 613-618.	1.9	5
641	Can Linear Regression Modeling Help Clinicians in the Interpretation of Genotypic Resistance Data? An Application to Derive a Lopinavir-Score. PLoS ONE, 2011, 6, e25665.	2.5	5
642	Alcohol, smoking, recreational drug use and association with virological outcomes among people living with HIV: crossâ€sectional and longitudinal analyses. HIV Medicine, 2021, , .	2.2	5
643	Estimation of HIV incidence from analysis of HIV prevalence patterns by age and years since starting sex work among female sex workers in Zimbabwe. Aids, 2022, Publish Ahead of Print, .	2.2	5
644	Impact of Mutations Conferring Reduced Susceptibility to Lamivudine on the Response to Antiretroviral Therapy. Antiviral Therapy, 2001, 6, 195-198.	1.0	5
645	Costs and cost-effectiveness of HIV early infant diagnosis in low- and middle-income countries: a scoping review. Infectious Diseases of Poverty, 2022, 11, .	3.7	5
646	Active drug injecting and progression of HIV infection. Aids, 1994, 8, 385-386.	2.2	4
647	Investigating temporal changes in the rate of HIV progression. Aids, 1997, 11, 1647-1649.	2.2	4
648	Survival after a very low (< 5 × 106/l) CD4+ T-cell count in individuals infected with HIV. Aids, 1997, 11, 1123-1127.	2.2	4

#	Article	IF	CITATIONS
649	Is 1 Alanine Transaminase >200 IU Enough to Define an Alanine Transaminase Flare in HIV-Infected Populations? A New Definition Derived From a Large Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, 391-396.	2.1	4
650	Early initiation of treatment for HIV infection. Lancet, The, 2010, 375, 639.	13.7	4
651	Non-uptake of highly active antiretroviral therapy among patients with a CD4 count < 350 cells/μL in the UK. HIV Medicine, 2012, 13, 73-78.	2.2	4
652	Rate of viral load failure over time in people on ART in the UK Collaborative HIV Cohort (CHIC) study. Journal of the International AIDS Society, 2014, 17, 19527.	3.0	4
653	Protease mutations emerging on darunavir in protease inhibitor-naÃ⁻ve and experienced patients in the UK. Journal of the International AIDS Society, 2014, 17, 19739.	3.0	4
654	O7â€Depression and sexual behaviour among men who have sex with men in the UK. Sexually Transmitted Infections, 2015, 91, A3.1-A3.	1.9	4
655	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. Journal of Antimicrobial Chemotherapy, 2016, 71, 1352-1360.	3.0	4
656	Longâ€ŧerm effectiveness of recommended boosted protease inhibitorâ€based antiretroviral therapy in Europe. HIV Medicine, 2018, 19, 324-338.	2.2	4
657	Associations between serum albumin and serious non-AIDS events among people living with HIV. Aids, 2018, 32, 1837-1848.	2.2	4
658	Effectiveness and Cost-Effectiveness of Treatment as Prevention for HIV. , 2017, , 91-111.		4
659	Challenges in modelling the proportion of undiagnosed HIV infections in Sweden. Eurosurveillance, 2019, 24, .	7.0	4
660	Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV. Journal of Virus Eradication, 2019, 5, 204-	29.5.	4
661	Clinical staging system for AIDS patients. Lancet, The, 1995, 346, 1103.	13.7	3
662	Unrecognised HIV infection among gynaecology patients. BJOG: an International Journal of Obstetrics and Gynaecology, 1996, 103, 470-473.	2.3	3
663	Treatment outcomes amongst previously antiretroviral-naÃ <sup>-</sup> ve HIV-infected patients starting lopinavir/ritonavir-containing antiretroviral regimens at the Royal Free Hospital*. HIV Medicine, 2007, 8, 55-63.	2.2	3
664	Are antiretrovirals enough for people living with HIV?. Lancet, The, 2013, 382, 1466-1467.	13.7	3
665	The importance of viral blips and duration of therapy initiated in primary infection in maintaining viral control after stopping cART. Journal of the International AIDS Society, 2014, 17, 19820.	3.0	3
666	Antiretroviral therapy recommendations for the global community. Aids, 2014, 28, 939-941.	2.2	3

#	Article	IF	CITATIONS
667	Antiretroviral dose reduction: good for patients and rollout. Lancet, The, 2014, 383, 1442-1443.	13.7	3
668	The importance of HIV RNA detection below 50 copies per mL in HIV-positive patients on antiretroviral therapy: an observational study. Lancet, The, 2014, 383, S44.	13.7	3
669	Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes. Medicine (United States), 2016, 95, e5133.	1.0	3
670	The Association between Detected drug Resistance Mutations and CD4 <sup>+</sup> T-Cell Decline in HIV-Positive Individuals Maintained on a Failing Treatment Regimen. Antiviral Therapy, 2018, 23, 105-116.	1.0	3
671	Antiretroviral Therapy and Mortality in Rural South Africa: A Comparison of Causal Modeling Approaches. American Journal of Epidemiology, 2018, 187, 1772-1779.	3.4	3
672	Which delivery model innovations can support sustainable HIV treatment?. African Journal of AIDS Research, 2019, 18, 315-323.	0.9	3
673	Risk factors for antiretroviral therapy (ART) discontinuation in a large multinational trial of early ART initiators. Aids, 2019, 33, 1385-1390.	2.2	3
674	Practical metrics for establishing the health benefits of research to support research prioritisation. BMJ Global Health, 2020, 5, e002152.	4.7	3
675	The Impact of Immediate InitiationÂofÂAntiretroviral Therapy on Patients' Healthcare Expenditures: A Stepped-Wedge Randomized Trial in Eswatini. AIDS and Behavior, 2021, 25, 3194-3205.	2.7	3
676	Relation Between Soluble CD30 Levels Measured Soon After HIV Seroconversion and Disease Progression in Men With Hemophilia. Journal of Acquired Immune Deficiency Syndromes, 1997, 16, 279-283.	0.3	3
677	Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapy. Antiviral Therapy, 2002, 7, 271-81.	1.0	3
678	Perspectives on the use of modelling and economic analysis to guide HIV programmes in sub-Saharan Africa. Lancet HIV,the, 2022, 9, e517-e520.	4.7	3
679	Trial and error: cross-trial comparisons of antiretroviral regimens. Aids, 2003, 17, 619-23.	2.2	3
680	Engagement in HIV services over time among young women who sell sex in Zimbabwe. PLoS ONE, 2022, 17, e0270298.	2.5	3
681	The Use of Backcalculation to Estimate the Prevalence of Severe Immunodeficiency Induced by Human Immunodeficiency Virus in England and Wales. Journal of the Royal Statistical Society Series A: Statistics in Society, 1994, 157, 41.	1.1	2
682	Prophylaxis for Pneumocystis carinii pneumonia: its impact on the natural history of HIV infection in men with haemophilia. Haemophilia, 1995, 1, 37-44.	2.1	2
683	RE: "HEIGHT AND THE RISK OF CARDIOVASCULAR DISEASE IN WOMEN". American Journal of Epidemiology, 1996, 144, 708-708.	3.4	2
684	Evaluating the effect of year of seroconversion on HIV progression in cohort studies. Aids, 1998, 12, 1353-1360.	2.2	2

#	Article	IF	CITATIONS
685	The influence of gender, social circumstances and smoking on survival. Public Health, 2000, 114, 117-122.	2.9	2
686	Indirect comparisons: a novel approach to assessing the effect of anti-HIV drugs. BMJ: British Medical Journal, 2004, 328, 253-253.	2.3	2
687	The incidence of HIV-related disease in a cohort of haemophilic men: natural history and changes since the introduction of pre-AIDS treatment. International Journal of Laboratory Hematology, 2008, 15, 241-251.	0.2	2
688	Monitoring of antiretroviral therapy in low-resource settings – Authors' reply. Lancet, The, 2008, 372, 289.	13.7	2
689	Cost-effectiveness of Strategies for Monitoring the Response to Antiretroviral Therapy in Resource-Limited Settings. Archives of Internal Medicine, 2009, 169, 904.	3.8	2
690	CD4 lymphocyte count as predictor of drug expenditure in a cohort of anti-HIV seropositive haemophiliacs. International Journal of Pharmacy Practice, 2011, 1, 210-211.	0.6	2
691	The Impact of HCV Infection Duration on HIV Disease Progression and Response to cART amongst HIV Seroconverters in the UK. PLoS ONE, 2015, 10, e0132772.	2.5	2
692	HIV Treatment-As-Prevention Research: Authors' Reply. PLoS Medicine, 2015, 12, e1001799.	8.4	2
693	Eligibility for PrEP among MSM attending GUM clinics in the UK. Sexually Transmitted Infections, 2017, 93, 571-571.	1.9	2
694	Plasma HIV-1 Tropism and the Risk of Short-Term Clinical Progression to AIDS or Death. PLoS ONE, 2017, 12, e0166613.	2.5	2
695	Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 102-109.	2.1	2
696	Benefits and Costs of the HIV/AIDS Targets for the Post-2015 Development Agenda. , 2018, , 277-286.		2
697	Improving the Validity of Mathematical Models for HIV Elimination by Incorporating Empirical Estimates of Progression Through the HIV Treatment Cascade. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 596-604.	2.1	2
698	HIV Treatment Substantially Decreases Hospitalization Rates: Evidence From Rural South Africa. Health Affairs, 2018, 37, 997-1004.	5.2	2
699	Impact of early antiretroviral treatment on sexual behaviour. Aids, 2019, 33, 2337-2350.	2.2	2
700	Attitudes to disclosure of HIV-serostatus to new sexual partners and sexual behaviours among HIV-diagnosed gay, bisexual and other men who have sex with men in the UK. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 1323-1332.	1.2	2
701	Willingness to pay for community delivery of antiretroviral treatment in urban Tanzania: a cross-sectional survey. Health Policy and Planning, 2021, 35, 1300-1308.	2.7	2

#	Article	IF	CITATIONS
703	Impact of Kaposi's sarcoma on HIV disease progression. Aids, 1999, 13, 286.	2.2	2
704	Response: Arguments contradict the "foreign protein-zidovudine" hypothesis. BMJ: British Medical Journal, 1996, 312, 211-212.	2.3	2
705	Implications for a policy of initiating antiretroviral therapy in people diagnosed with human immunodeficiency virus: the CAPRA research programme. Programme Grants for Applied Research, 2017, 5, 1-40.	1.0	2
706	Differentiated prevention and care to reduce the risk of HIV acquisition and transmission among female sex workers in Zimbabwe: study protocol for the â€~AMETHIST' cluster randomised trial. Trials, 2022, 23, 209.	1.6	2
707	PrEP uptake and delivery setting preferences among clients visiting six healthcare facilities in Eswatini. AIDS and Behavior, 2022, 26, 3345-3355.	2.7	2
708	Viral breakthrough after suppression with highly active antiretroviral therapy: experience from 233 individuals with viral loads of less than 50 copies/ml followed for up to 4 years. Aids, 2003, 17, 768-70.	2.2	2
709	Blood cholesterol, social class and height. Journal of Public Health, 1990, 12, 142-143.	1.8	1
710	Female-to-Male Transmission of HIV. JAMA - Journal of the American Medical Association, 1992, 268, 1855.	7.4	1
711	Changes in Lymphocyte Subsets in Human Immunodeficiency Virusâ€Positive Persons with <5 CD4 T Lymphocytes/mm <sup>3</sup> . Journal of Infectious Diseases, 1998, 178, 1166-1169.	4.0	1
712	The influence of gender, social circumstances and smoking on survival the Renfrew and Paisley study. Public Health, 2000, 114, 117-122.	2.9	1
713	When to Start Therapy. Journal of Infectious Diseases, 2005, 191, 821-821.	4.0	1
714	Issues in the design of trials comparing management strategies for heavily pretreated patients. Current Opinion in HIV and AIDS, 2006, 1, 476-481.	3.8	1
715	Has Human Immunodeficiency Virus Become More Virulent?. Clinical Infectious Diseases, 2009, 48, 1293-1295.	5.8	1
716	Rescue of Severely Immunocompromised HIVâ€Positive Persons. Journal of Infectious Diseases, 2010, 202, 1467-1469.	4.0	1
717	Predictors of having a resistance test following confirmed virological failure of combination antiretroviral therapy: data from EuroSIDA. Antiviral Therapy, 2011, 16, 781-785.	1.0	1
718	The role of individual-based models in understanding the potential impact of antiretroviral therapy for prevention. Aids, 2012, 26, 1441-1442.	2.2	1
719	Plasma HIV-1 tropism and risk of short-term clinical progression to AIDS or death. Journal of the International AIDS Society, 2014, 17, 19685.	3.0	1
720	Early virological response to HIV treatment: can we predict who is likely to experience subsequent treatment failure? Results from an observational cohort study, London, UK. Journal of the International AIDS Society, 2017, 20, 21567.	3.0	1

#	Article	IF	CITATIONS
721	Cross-Sectional Studies in AIDS Pathogenesis. Journal of Acquired Immune Deficiency Syndromes, 1997, 14, 153-157.	0.3	1
722	Alcohol and ischaemic heart disease in middle aged British men:: Author's reply. BMJ: British Medical Journal, 1987, 294, 1288-1289.	2.3	0
723	Collinearity and imprecision in dietary measurement. Journal of Clinical Epidemiology, 1992, 45, 681.	5.0	0
724	Applications of CD4 Counts in a Cohort of HIV-1 Seropositive Patients with Haemophilia1. , 1992, , 32-45.		0
725	Progression of occlusive renal vascular disease and axillofemoral bypass grafts. Nephrology Dialysis Transplantation, 0, , .	0.7	Ο
726	Small numbers and poor measurements. Journal of Clinical Epidemiology, 1994, 47, 959-960.	5.0	0
727	The Association Between HIV Phenotype, Virus Burden, Codon 215 Mutation and CD4 Cell Decline. Journal of Acquired Immune Deficiency Syndromes, 1995, 9, 101.	0.3	Ο
728	The epidemiology of HIV disease in men with haemophilia in the UK. Haemophilia, 1995, 1, 6-7.	2.1	0
729	Early assessment of anti-HIV drug efficacy. Lancet, The, 2002, 359, 1696-1697.	13.7	Ο
730	Relating protease inhibitor resistance at time of virological failure with drug exposure. Journal of the International AIDS Society, 2010, 13, P118.	3.0	0
731	Haemoglobin and anaemia in the SMART study. Journal of the International AIDS Society, 2010, 13, P144.	3.0	0
732	Authors' response to Drs Scourfield, Jackson and Nelson. HIV Medicine, 2011, 12, 450-451.	2.2	0
733	Detection of resistance mutations and CD4 slopes in individuals experiencing sustained virological failure. Journal of the International AIDS Society, 2014, 17, 19737.	3.0	Ο
734	O21.3â€Pre-therapy inflammation/coagulation activation and long-term cd4 response to antiretroviral therapy. Sexually Transmitted Infections, 2015, 91, A73.1-A73.	1.9	0
735	Language used to convey HIV infection risk is important – Authors' reply. Lancet HIV,the, 2018, 5, e272.	4.7	Ο
736	Sex partners as bystanders in HIV prevention trials: Two test cases for research ethics. Clinical Trials, 2019, 16, 455-457.	1.6	0
737	The effect of eligibility for antiretroviral therapy on body mass index and blood pressure in KwaZulu-Natal, South Africa. Scientific Reports, 2021, 11, 14718.	3.3	0
738	CD4 Counts as Surrogate Markers for Progression to AIDS. Annals of Internal Medicine, 1994, 120, 87.	3.9	0

#	Article	IF	CITATIONS
739	Early virological response to HIV treatment: can we predict who is likely to experience subsequent treatment failure? Results from an observational cohort study, London, UK. Journal of the International AIDS Society, 2017, 20, 21567.	3.0	0